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A Novel Mechanism of Enhanced Susceptibility to Bacterial Pneumonia in
Influenza-infected Hosts
Abstract
Viruses such as influenza suppress host immune function by a variety of methods. This may result in a
significant morbidity through several pathways, including facilitation of secondary bacterial pneumonia
from pathogens such as Streptococcus pneumoniae. Lungresident alveolar macrophages (AMs) act as
the first line of innate cellular immunity against respiratory bacterial pathogens, including pneumococcus.
Therefore, they represent an attractive target for study Before investigating the impact of influenza
infection on resident AMs, we first characterized different subsets of lung-resident macrophages in naïve
mice using a novel in vivo labeling approach in conjunction with multicolor flow cytometric analysis and
confocal microscopic examination. A stable fluorescent dye, PKH26-PCL, was administered intranasally
to selectively label the lung-resident macrophages in a well-established murine model prior to influenza
infection. We determined the turnover kinetics of the lung-resident macrophage subsets during the course
of influenza infection. More than 90% of resident AMs were lost in the first week after influenza, while the
remaining cells had a necrotic phenotype. To establish the impact of this innate immune defect, influenzainfected mice were challenged with a small dose of Streptococcus pneumoniae. Early AM-mediated
bacterial clearance was significantly impaired during the AM depletion phase in influenza-infected mice –
about 50% of the initial bacterial inoculum could be harvested from the alveolar airspaces 3 hours later. In
mock-infected mice, by contrast, more than 95% of inocula up-to-50-fold higher was efficiently cleared.
Co-infection during the AM depletion phase caused significant body weight loss and mortality. Two weeks
after influenza, the AM population was fully replenished with successful re-establishment of the early
innate host protection. Local GM-CSF treatment induced partial expansion of resident AMs during
influenza infection. Thus, it led to partial restoring of the impaired early bacterial clearance with efficient
protection against secondary pneumococcal pneumonia. We conclude that a novel immunosuppression
mechanism occurs during influenza infection through the resident AM depletion. Among other potential
effects, this establishes a niche for secondary pneumococcal infection by altering early cellular innate
immunity in the lungs resulting in pneumococcal outgrowth and lethal pneumonia. This novel mechanism
will inform development of novel therapeutic approaches to restore lung innate immunity against
bacterial super-infections. Secondary bacterial pneumonia (SBP) is a leading cause of the increased
hospitalizations and mortality during influenza epidemics and pandemics despite routine use of standard
antibiotics. Antibiotic-induced immunopathology associated with bacterial cell wall lysis has been
suggested to contribute to these poor outcomes. Using Streptococcus pneumoniae in a wellestablished
murine model of SBP following influenza, we stratified disease severity based on the pneumococcal load
in the lungs via in vivo bioluminescence imaging. Ampicillin treatment cured mice with mild pneumonia
but was ineffective against severely pneumonic mice, despite effective bacterial killing. This treatment
failure makes it crucial to explore immunmodulation approaches that can prevent the aggravated lung
immunopathology during antibiotic treatment of severe SBP. Therefore, we tested the efficacy of the
standard anti-inflammatory drug dexamethasone as an adjunctive corticosteroid therapy. Adjunctive
dexamethasone treatment significantly improved ampicillin-induced immunopathology and survival
outcomes in mice with severe SBP. However, early dexamethasone therapy during primary influenza
infection impaired the adaptive immunity in the lungs as manifest by increased viral titers, with an
associated loss of its protective functions in SBP. The clinical use of corticosteroids as an adjunctive
therapy for treating pneumonia is still under debate. However, our findings support adjunctive clinical use
of corticosteroids in severe cases of community-acquired pneumonia. Nonetheless, dexamethasone
treatment has drawbacks implied by delayed body weight recovery in dexamethasone-treated mice, which
may explain the published controversy on the corticosteroid efficacy in terms of disease morbidity. This
relative success of our animal model of SBP to simulate the clinical therapeutic settings in humans will
help explore novel immunomodulation approaches to improve the poor outcomes of antibiotic treatment

of severe community-acquired pneumonia.
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ABSTRACT
Viruses such as influenza suppress host immune function by a variety of methods.
This may result in a significant morbidity through several pathways, including facilitation
of secondary bacterial pneumonia from pathogens such as Streptococcus pneumoniae.
Lung-resident alveolar macrophages (AMs) act as the first line of innate cellular
immunity against respiratory bacterial pathogens, including pneumococcus. Therefore,
they represent an attractive target for study.
Before investigating the impact of influenza infection on resident AMs, we first
characterized different subsets of lung-resident macrophages in naïve mice using a novel
in vivo labeling approach in conjunction with multicolor flow cytometric analysis and
confocal microscopic examination. A stable fluorescent dye, PKH26-PCL, was
administered intranasally to selectively label the lung-resident macrophages in a wellestablished murine model prior to influenza infection. We determined the turnover
kinetics of the lung-resident macrophage subsets during the course of influenza infection.
More than 90% of resident AMs were lost in the first week after influenza, while the
remaining cells had a necrotic phenotype.
To establish the impact of this innate immune defect, influenza-infected mice
were challenged with a small dose of Streptococcus pneumoniae. Early AM-mediated
bacterial clearance was significantly impaired during the AM depletion phase in
influenza-infected mice – about 50% of the initial bacterial inoculum could be harvested
from the alveolar airspaces 3 hours later. In mock-infected mice, by contrast, more than
95% of inocula up-to-50-fold higher was efficiently cleared. Co-infection during the AM
depletion phase caused significant body weight loss and mortality. Two weeks after
influenza, the AM population was fully replenished with successful re-establishment of
the early innate host protection. Local GM-CSF treatment induced partial expansion of
resident AMs during influenza infection. Thus, it led to partial restoring of the impaired
early bacterial clearance with efficient protection against secondary pneumococcal
pneumonia.
We conclude that a novel immunosuppression mechanism occurs during influenza
infection through the resident AM depletion. Among other potential effects, this
establishes a niche for secondary pneumococcal infection by altering early cellular innate
immunity in the lungs resulting in pneumococcal outgrowth and lethal pneumonia. This
novel mechanism will inform development of novel therapeutic approaches to restore
lung innate immunity against bacterial super-infections.
Secondary bacterial pneumonia (SBP) is a leading cause of the increased
hospitalizations and mortality during influenza epidemics and pandemics despite routine
use of standard antibiotics. Antibiotic-induced immunopathology associated with
bacterial cell wall lysis has been suggested to contribute to these poor outcomes. Using
Streptococcus pneumoniae in a well-established murine model of SBP following
influenza, we stratified disease severity based on the pneumococcal load in the lungs via
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in vivo bioluminescence imaging. Ampicillin treatment cured mice with mild pneumonia
but was ineffective against severely pneumonic mice, despite effective bacterial killing.
This treatment failure makes it crucial to explore immunmodulation approaches that can
prevent the aggravated lung immunopathology during antibiotic treatment of severe SBP.
Therefore, we tested the efficacy of the standard anti-inflammatory drug
dexamethasone as an adjunctive corticosteroid therapy. Adjunctive dexamethasone
treatment significantly improved ampicillin-induced immunopathology and survival
outcomes in mice with severe SBP. However, early dexamethasone therapy during
primary influenza infection impaired the adaptive immunity in the lungs as manifest by
increased viral titers, with an associated loss of its protective functions in SBP. The
clinical use of corticosteroids as an adjunctive therapy for treating pneumonia is still
under debate. However, our findings support adjunctive clinical use of corticosteroids in
severe cases of community-acquired pneumonia. Nonetheless, dexamethasone treatment
has drawbacks implied by delayed body weight recovery in dexamethasone-treated mice,
which may explain the published controversy on the corticosteroid efficacy in terms of
disease morbidity. This relative success of our animal model of SBP to simulate the
clinical therapeutic settings in humans will help explore novel immunomodulation
approaches to improve the poor outcomes of antibiotic treatment of severe communityacquired pneumonia.
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CHAPTER 1.

INTRODUCTION

Influenza Viruses
Classification and Ecology
Influenza viruses are members of the Orthomyxoviridae family. They encompass
a wide variety of strains that cause significant respiratory infections in humans and
various animals. Influenza viruses are antigenically classified into three genera: A, B, and
C. Influenza A viruses can be further subtyped based on their two surface glycoproteins
antigens: hemagglutinin (HA) and neuraminidase (NA) [1]. So far, 16 HA subtypes and 9
NA subtypes have been identified [2, 3]. Standard nomenclature of influenza viruses
includes virus genus, species from which it was isolated (if non-human), location where it
was isolated, isolate number, and isolate year. HA and NA subtypes are added for
influenza A viruses [4]. An example nomenclature of an influenza virus commonly used
in the laboratory is influenza virus A/Puerto Rico/8/34 (H1N1).
The primary reservoir for influenza A viruses is aquatic birds. However, they can
infect several hosts including pigs, horses, whales, seals, minks and humans. The
reported ability of interspecies transmission of influenza A viruses is a major source for
new pandemic strains with serious consequences on public and veterinary health [5-8].
Structure of Influenza A Viruses
Influenza A viruses are defined as enveloped RNA viruses. The viral capsid is
surrounded by a lipid bilayer envelope acquired from the host cell membrane during viral
particle release. The influenza A viral genome consists of 8 segmented, negative, singlestranded RNA genes. These genes encode for up to 11 known proteins, due to two splice
variants of non-structural (NS) and matrix (M) genes, in addition to a product of an
alternate open reading frame of polymerase basic 1 gene (PB1) in some influenza A virus
strains, known as PB1-F2 [9]. Influenza viral proteins have different functions and spatial
positions. Three of them are integral in the lipid envelope – HA and NA are embedded in
the envelop as the major surface glycoprotein spikes, while a splice variant of M gene
called matrix protein (M2) forms ion channels traversing the envelope [10]. This studded
envelop overlays a coat composed of another matrix protein (M1). These outer layers
enclose the viral core containing non-structural protein 2 (NS2) and the ribonucleoprotein
complex (RNP), which consists of viral RNA segmented genes coated with nucleoprotein
(NP) and RNA-dependent RNA polymerase. The viral RNA polymerase is composed of
3 subunits: 2 polymerase basic subunits (PB1 and PB2) and 1 polymerase acidic subunit
(PA) (Figure 1-1) [4, 11]. Recently, a novel viral protein, termed PA-X, was identified as
the product of the second open reading frame of PA gene which can be accessed through
ribosomal frameshifting [12].
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Figure 1-1.

Influenza A virus structure

Reprinted with permission from Dr. Ian M. Mackay. Virology Down Under,
http://www.uq.edu.au/vdu/ (Last accessed on September 5, 2013) [11].
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Replication Cycle
The influenza A virus replication cycle starts by virus attachment through HA
spikes on the viral envelope to terminal N-acetylneuraminic (sialic) acid moieties on the
host cell surface. The type of linkage of these terminal sialic acid moieties to galactose
determines viral tropism to host cells, as HA may have preferential binding to sialic acid
receptors with either α-2,3 or α-2,6 linkages [13]. Generally, HA of human influenza
viruses binds preferentially to sialic acid with α-2,6 linkage, which is more abundant on
human tracheal epithelial cells [14, 15], whereas HA of avian influenza viruses binds to
sialic acid with α-2,3 linkage [13, 16, 17], which is abundant on gut and respiratory
epithelial cells of ducks [18].
Upon HA binding to the host cell sialic acid residues, receptor-mediated
endocytosis occurs. The virus enters the host cell in a clathrin-coated endosome, whose
acidic pH triggers a conformational change of HA leading to fusion of the viral and
endosomal membranes, followed by release of nucleocapsid into the cell cytoplasm [19].
In addition, M2 channels in the viral envelope pump hydrogen protons into the viral core.
This internal acidification process disrupts internal protein-protein interactions, causing
the M1 protein to dissociate from RNP and eventually leading to viral uncoating and
release of viral RNP into the cell cytoplasm [4, 20].
After their cytosol release, viral RNPs are actively translocated to the host cell
nucleus through nuclear localization signals on internal viral proteins [21]. Upon entering
the nucleus, transcription and replication processes of the viral genome start. Viral RNA
serves as a template for mRNA and complementary positive-stranded RNA (cRNA)
synthesis. Next, viral mRNA is exported out of the nucleus to be translated into viral
proteins. cRNA is amplified into genomic viral RNAs, which associate with internal viral
proteins, forming newly synthesized viral RNP segments. Nuclear export of the progeny
viral RNP segments into the cytoplasm is mediated by M1 and nuclear export protein
(NEP)/NS2 proteins [4, 21]. Then, they are transported to the cell membrane – the site of
viral RNP segments packaging and assembling of the new viral particles. Growing
evidence suggests that the packaging process of eight unique viral RNP segments is a
selective, yet unclear, process [22, 23]. M1 protein is accumulated at the cytoplasmic side
of the lipid bilayer which facilitates viral budding. Finally, NA protein through its
sialidase activity cleaves terminal sialic acid residues on both the host cell surface and the
viral envelope to facilitate the release of new viral particles, and prevent aggregation of
viral particles, respectively [4, 24].
Pathogenesis in Humans
Influenza and pneumonia remain among the leading causes of deaths worldwide.
Influenza A viruses can cause acute respiratory viral infections that can be easily
transmitted among humans by inhalation of respiratory droplets. They have been
circulating since at least the 16th century with a unique ability to cause recurrent annual
epidemics [25]. Moreover, upon emergence of a novel influenza virus, by which the total
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population has not been attacked before and consequently people have no specific
adaptive immunity against, this novel virus spreads quickly among different age groups
and healthy young individuals of the population with rapid transmission to several
regions worldwide leading to influenza pandemics. Several such pandemics occurred in
the 20th century causing millions of deaths worldwide. The specter of influenza
pandemics still imposes a continuous threat to world public health in the 21st century,
after the recent swine H1N1 influenza pandemic emerged in 2009-2010 and caused more
than 284,000 deaths globally in the first year [26, 27].
In humans, acute influenza infections cause diseases of variable severity, ranging
from mild upper respiratory tract infections to acute respiratory distress syndrome and
death. Several factors count for the variability in infection outcomes. Therefore, it is
crucial to understand factors related to the virus and the host which contribute to
increased morbidity and mortality.
Viral Virulence
Viral virulence is a complex phenomenon which involves several factors,
including viral tropism, transmissibility, and replication efficiency [28]. It is a multigenic
trait, resulting from the collective contribution of different viral genes and proteins into
viral pathogenicity. However, certain viral genes from some highly virulent influenza
strains may increase virulence if put into the genetic background of another strain. For
example, studies of recombinant strains produced by a reverse genetics system using HA
and NA genes or even a single HA gene from the highly virulent 1918 pandemic
influenza strain plus the genetic background of another strain increased the recombinant
virus virulence in mice [26, 29, 30]. Strikingly, just one mutation in a certain gene of
some strains may greatly affect their virulence [26].
Circulating highly virulent influenza viruses pose a continuous threat of a new
serious influenza pandemic. An example of recently emerged highly pathogenic influenza
strains that have pandemic potential is the avian H5N1 influenza viruses, which caused
high fatality rate of about 60% in the identified infected humans [31]. However, they
have poor human-to-human transmission and remain endemic in poultry populations,
mostly in Southeast Asia [6]. Nonetheless, recent studies showed that these highly
pathogenic viruses may naturally adapt and acquire efficient human-to-human
transmission, posing a great threat to humans [32, 33]. With currently limited spread
among humans, these highly pathogenic avian viruses have given only minor contribution
to global influenza-associated morbidity and fatality with 378 deaths among cumulative
637 cases of infection from 2003 until August 2013 [34].
In general, it has been observed that influenza viral infections alone do not
account for most mortality during seasonal, epidemic, or pandemic influenza periods.
Instead, complications during influenza infections were found as the main reasons for
increased influenza-associated mortality. For instance, people with certain comorbidities
are considered high-risk populations during influenza epidemics and pandemics, and
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antiviral therapy is highly recommended for them. This high-risk category includes those
with weakened immunity, such as infants and children less than 5 years old, as well as the
elderly, pregnant women, and people with serious respiratory or cardiovascular diseases.
Additionally, bacterial super-infections remain a serious complication among all
influenza-infected hosts and were found to complicate many severe cases of influenza
infections and significantly contribute to fatalities during influenza epidemics and
pandemics [35, 36].
Despite its importance, viral virulence is primarily a threat to immunologically
naïve hosts. Therefore, highly pathogenic viruses may only have minor effects on healthy
individuals with previous exposure or those who were vaccinated against closely related
viral strains. Thus, host immunity is another key factor in virus-host interactions and
influenza infection outcomes.
Host Immune Responses
Host immunity can be classified into two branches: innate non-specific immunity
and adaptive specific immunity. Once the influenza virus enters its target cell and starts
replication in the respiratory tract, diverse host immune responses launch, starting with
initial responses of infected cells and progressing to more advanced and specific immune
responses. To initiate host immune responses, a pathogen or its associated pathogenic
activity must be detected. Detection is performed by receptors in the host cells called
pattern recognition receptors (PRRs). These receptors play key roles in the innate
immune response to infections by a wide range of microorganisms, including influenza
viruses. PRRs are activated when they detect and bind to certain conserved microbespecific motifs or molecules, known as pathogen-associated molecular patterns (PAMPs).
PPRs can also detect certain host endogenous molecules released during tissue damage
called damage-associated molecular patterns (DAMPs). PRRs are composed of diverse
sets of receptors including Toll-like receptors (TLRs), nucleotide oligomerization domain
(NOD)-like receptors (NLRs), retinoic acid inducible gene-I (RIG-I)-like receptors
(RLRs), and cytosolic DNA and viral RNA sensors. Some of them are expressed on the
surface of host cells, including TLR1, TLR2, TLR4, TLR5, and TLR6, making them
suitable for detecting extracellular pathogens and certain DAMPs. However, other PRRs,
such as TLR3, TLR7, and TLR9, and RLRs, present intracellularly in the endosomes or
host cell cytosol to detect intracellular pathogens [37, 38].
Activation of various PRRs during influenza virus replication triggers certain
signaling pathways in the detecting host cells, eventually leading to synthesis of different
cytokines and chemokines (Figure 1-2) [28]. Infected respiratory epithelial cells and
pulmonary macrophages are the first cells to detect viral replication. Three main
categories of PRRs can detect influenza virus infection: TLRs, such as TLR3 and TLR7,
which bind to viral double-stranded RNA and single-stranded RNA, respectively; RIG-I
receptors which recognize newly synthesized viral RNAs [39]; and NLR receptor family
pyrin domain containing 3 (NLRP3), which is activated by influenza viral RNA or M2
ion channel activity during influenza infection [40-42]. Some of the cytokines produced
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Figure 1-2.

Molecular basis of immune responses at site of influenza infection

Reprinted with permission from Elsevier. Salomon R, Webster RG. The influenza virus
enigma. Cell 2009; 136:402-10 [28].
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early have strong antiviral activities, such as type I interferons (IFNα/β) and type III IFN
(IFNλ), which protect nearby non-infected cells against influenza infection by inducing
synthesis of various antiviral proteins. In addition, they stimulate dendritic cells to
enhance antigen presentation for T cells, thereby facilitating adaptive immune response
development. Inflammatory response may be blocked in the first 2 days after influenza
infection but then pro-inflammatory cytokines and chemokines are suddenly released
signaling recruitment and activation of various circulating immune cells to the site of
infection (Figure 1-2) [43-45].
Several types of host immune cells are recruited to the infection site with different
kinetics and different performance characteristics but temporally integrated functions.
Extravasation of innate immune cells, such as neutrophils, natural killer cells, exudate
monocytes and macrophages, and dendritic cells start in the first few days after infection.
Then, activated influenza-specific adaptive immune cells are recruited with more targeted
functions in fighting influenza virus infection. After viral clearance, these influenzaspecific adaptive immune cells play a critical protective role against future re-infections
by the same or closely related strains by establishing influenza-specific memory
immunity (Figure 1-3) [46].
Because of their spatial position on the mucosal surface of alveolar epithelium,
resident alveolar macrophages (AMs) are the first innate immune cells to encounter
influenza virus upon its spread to the lower respiratory tract. They detect early virus
replication and become activated, releasing several pro-inflammatory cytokines and
chemokines. Thereby, they signal recruitment of innate immune cells that participate in
controlling viral replication during the inflammatory phase of infection. Different
influenza A virus strains have different abilities to infect human and murine AMs [47].
However, infected AMs produce low virus yield. AMs were thought for a long time to be
a central activator for the induced inflammatory cytokine storm when they are infected by
the highly pathogenic H5N1 influenza viruses [43]. In contrast, a recent study strikingly
showed that human AMs, and not blood monocyte-derived macrophages, can release
only small amounts of pro-inflammatory cytokines after being infected by different
influenza viruses, including highly pathogenic H5N1 viruses [48]. These data are
relatively relevant with the observed immunosuppressive nature of AMs [49, 50]. In
contrast, another study showed that influenza infections of isolated human AMs induce
robust release of different cytokines and chemokines, including type I IFN, while
downregulating expression of certain receptors, such as, macrophage scavenger receptor
1 and CD36 [51].
Dendritic cells (DCs) are generally professional antigen-presenting cells (APCs)
that bridge innate and adaptive immunity. Their activation during influenza infection
enhances the uptake, processing, and presentation of influenza antigens. Thereafter, some
DCs migrate to the draining lymph nodes (DLNs) where they present influenza antigenic
epitopes on either major histocompatibility complex (MHC) class I and II molecules to
CD8+ T cells and CD4+ helper T (Th) cells, respectively. This step is crucial for the
initiation of adaptive immune responses. In mouse models of influenza infection, several
subsets of DCs, such as migratory CD103+ CD11b- conventional DCs and CD11b+ DCs,
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Figure 1-3. Kinetics of adaptive immune responses during primary and
secondary influenza infections
Reprinted with permission from Elsevier. Subbarao K, Murphy BR, Fauci AS.
Development of effective vaccines against pandemic influenza. Immunity 2006; 24:5-9
[46].
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have been identified to be crucial for mounting efficient adaptive immunity against
influenza viruses. They carry influenza antigens from the site of infection and migrate to
the DLNs to prime and activate expansion of influenza-specific T cells. In addition,
monocyte-derived DCs may be necessary to sustain effector T cells in the lungs for viral
clearance [52]. In contrast, some inflammatory DCs may also cause detrimental
immunopathology in the lungs during lethal influenza infection [53-55].
Natural killer (NK) cells are also important innate immune effector cells. They
can directly kill influenza-infected cells after triggering their cytotoxicity receptors, such
as NKp44 and NKp46, by binding to influenza HA proteins expressed on influenzainfected cells. In addition, antibody-dependent cellular cytotoxicity (ADCC) is another
mechanism in which NK cells lyse antibody-bound influenza-infected cells after binding
their CD16 receptor (FcγRIII) to the Fc portion of the bound antibodies [43, 56].
Neutrophil influx is a hallmark of the early innate immune response to influenza
infection. Neutrophils significantly participate in limiting influenza viral replication in
the early inflammatory phase of infection. Furthermore, they may also facilitate the
initiation of adaptive immune responses. They release different cytokines and
chemokines that signal recruitment and activation of DCs. In addition, they may
modulate the activities of T cells [57-59]. On the other hand, if neutrophil influx and their
pro-inflammatory functions are not tightly controlled, they may remarkably contribute to
lung immunopathology and increased morbidity and lethality [60, 61].
Exudate monocytes and macrophages also participate in the inflammatory innate
immune response to influenza infection. Their infiltration is induced by different proinflammatory cytokines and chemokines released from infected cells and virus-detecting
immune cells, such as pulmonary macrophages and DCs. This process is mainly CCR2dependent preferentially recruiting CCR2+ mononuclear phagocytes. They contribute in
limiting viral spread via phagocytosis of infected apoptotic bodies. However, they may
also become destructive causing immunopathology by enhancing the release of proinflammatory cytokines and tissue-damaging species, such as tumor necrosis factor-α,
interleukin-6 (IL-6), and nitric oxide [54]. Thus, prophylactic CCR2-antagonist treatment
significantly attenuated lung immunopathology without affecting viral clearance and
improved survival in a mouse model of severe influenza infection [62].
A few days after launching the acute inflammatory innate immune response, the
influenza infection becomes more efficiently controlled by influenza-specific B cells and
CD8+ T cells, both effectors of antibody-mediated (humoral) and cell-mediated (cellular)
adaptive immunity (Figure 1-3 and Figure 1-4). They are initially activated in the
secondary lymphatic tissues, such as the DLNs, after recognizing influenza antigenic
epitopes presented on MHC class I and II molecules on the surface of activated APCs
expressing co-stimulatory molecules with the help of activated CD4 + Th cells. After
activation and clonal expansion, influenza-specific B cells and T cells migrate to an
influenza infection site under chemoattractant gradient. Specific T cell receptors on the
surface of CD8+ cytotoxic T cells recognize influenza antigenic epitopes presented on
MHC class I molecules on influenza-infected host cells. They kill infected cells via
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Figure 1-4.

Adaptive immune response against influenza virus infection

Adapted with permission from Nature Publishing Group. Subbarao K, Joseph T.
Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev
Immunol 2007; 7:267-78 [63].

10

perforin-mediated cytolysis and granzymes and FAS/FASL-induced apoptosis. In
addition, plasma cells secrete antibodies targeting several influenza antigenic epitopes,
especially surface antigens HA, NA, and M2, which neutralize the infectivity of influenza
viral particles (Figure 1-4). Furthermore, influenza-specific antibodies bound to viral
particles facilitate their clearance and phagocytosis by binding to Fc receptors of various
phagocytes. They also bind to influenza antigens expressed on the surface of infected
cells and activate their killing by the NK cell ADCC mechanism [43].
After viral clearance, some virus-specific B cells and T cells differentiate into
memory cells. They reside mainly in some lymphoid organs and structures, such as the
spleen and inducible bronchus-associated lymphoid tissue, establishing specific memory.
Their protective functions rely on their ability to launch faster specific adaptive immune
responses against future infections by the same or closely related influenza virus strains
(Figure 1-3).
Indeed, efficient innate and adaptive host immune responses are required to
inhibit viral replication and facilitate viral clearance. On the other hand, excessive
immune responses will have deleterious effects and cause collateral lung tissue damage.
Therefore, respiratory epithelial cells and other effectors play important roles to restore
lung homeostasis during influenza infections and to prevent the damaging effects of
robust host immune responses. For example, lung epithelial cells are highly expressing
inhibitory molecule CD200 which inhibits inflammatory activation of recruited
macrophages in addition to AMs by binding to CD200 receptor. Moreover, lung
epithelial cells constitutively express latent TGF-β which was shown to maintain
pulmonary immunological homeostasis under steady state. It can get activated by
influenza NA activity. In vivo blockage of TGF-β during influenza infection was shown
to increase disease morbidity, implying its potential immunomodulatory activity [55, 64,
65].
Immune Evasion by Influenza Viruses
To be successful against the elaborate host immunity, influenza viruses use a
variety of strategies to evade host immune responses. Several viral proteins have been
shown to antagonize antiviral innate immune responses and alter the type I IFN response.
For example, functional influenza NS1 protein can interfere with RIG-I receptor
signaling at several stages. Furthermore, NS1 may also impair DC maturation, thereby
indirectly limiting adaptive immunity development. Other viral proteins, including PB2,
PB1-F2, PB1, and PA also have antagonistic activities against the type I IFN response
[56, 66, 67].
More strikingly, influenza viruses have a unique ability to change their genome.
Thus, they can evade host adaptive immunity post continuous threats to humans, even to
a vaccinated populations. Influenza viruses can undergo two types of antigenic changes:
antigenic shift and antigenic drift. Antigenic shift leads to major changes in the viral
genome through a reassortment process between genes of different influenza virus strains
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in a cell simultaneously infected with two of more strains. These reassortment events
mostly take place in avian or swine reservoirs, resulting in the emergence of a new strain
that can be transmitted to and circulate among hosts of the same species or transmitted to
humans, causing recurrent epidemics or global pandemics. In contrast, antigenic drift
results from mutations in viral genes due to the lack of proofreading activity of influenza
viral RNA polymerase. This leads to minor changes in the antigenic epitopes of the virus,
mostly in the surface antigens HA and NA. These random mutations are preserved under
selective pressure of the host influenza-specific adaptive immunity, generating escape
mutant strains [43, 56].
Streptococcus pneumoniae
History
Streptococcus pneumoniae, also commonly known as pneumococcus, is among
the first discovered bacterial pathogens causing human diseases. In 1881, pneumococcus
was independently isolated by George M. Sternberg in the United States and Louis
Pasteur in France. They described lancet-shaped pairs of spherical bacteria in human
saliva. They showed that a new septicemic disease developed rapidly after injecting
rabbits with human saliva, and recovered the same bacteria from infected rabbit blood
[68].
After several nominations, pneumococcus was named Diplococcus pneumoniae in
1920 due to its observed morphology as pairs of cocci, and its commonly reported ability
to cause pneumonia in humans [69]. In 1974, it was renamed Streptococcus pneumoniae,
as it grows in chains in liquid media [68].
Since the discovery of pneumococci in the 19th century, they have been heavily
investigated and played a central role in several breakthrough discoveries. For example,
studies on pneumococci expanded our understanding of the concept of host humoral
immunity and the vaccine production, and facilitated the discovery of DNA as genetic
material which gave rise to Molecular Genetics [68, 70, 71]. Moreover, it accelerated the
development and use of penicillin and related antibiotics after they showed efficacy in
treating pneumococcal infections [72, 73].
Identification
Pneumococci are Gram-positive bacteria belonging to Streptococcus genus which
are catalase-negative and can ferment glucose to lactic acid. However, pneumococci
produce alpha-hemolysis when grown on blood agar plates under 5% CO2 conditions.
Identification through special biochemical tests is based on pneumococcal ability to
hydrolyze inulin, and its sensitivity to optochin and bile salt [74]. Further classification is
based on serotyping. The pneumococcus is surrounded by a polysaccharide capsule that
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is highly antigenic, inducing specific serum antibodies. Antigenic classification of the
pneumococcal capsule is performed by a capsular swelling test or quellung reaction,
which allows identification of more than 90 capsular serotypes [75-77].
Virulence Factors
Pneumococci reside on the mucosal surface of the upper respiratory tract of
asymptomatic carriers who are the primary reservoir of S. pneumoniae, from which it can
be transmitted to other individuals by inhalation of respiratory droplets. Alternatively, it
can spread locally to cause upper or lower respiratory tract infections. It can also invade
the blood, causing septicemia and meningitis.
This clinically challenging pathogen has a diverse armament of virulence factors
helping it switch from the colonization state to a pathogenic nature that causes respiratory
tract infections or septicemia (Figure 1-5). One of the key virulence factors is the
polysaccharide capsule, which resists phagocytosis in the absence of capsule-specific
antibodies. It acts as a shield, preventing complement C3b deposition on the bacterial cell
wall, thereby protecting the bacteria against opsonin-mediated phagocytosis. It also
decreases the trapping of pneumococci in neutrophil extracellular traps [76]. Differences
in the capsular structure led to the identification of more than 90 capsular serotypes with
varying degrees of virulence [76].
The pneumococcal cell wall has characteristic teichoic acid residues attached to
the peptidoglycan in addition to lipoteichoic acid attached to the bacterial cell membrane.
Both moieties have phosphorylcholine, which can bind to choline-binding receptors on
the surface of human cells. In addition, there are several types of pneumococcal surface
proteins that play important roles in bacterial adherence, colonization, in vivo growth,
and virulence. Among these surface proteins are choline-binding proteins, including
pneumococcal surface proteins A and C (PspA and PspC); metal-binding proteins,
including pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A
(PiaA), and pneumococcal iron uptake A (PiuA); and pneumococcal adhesion and
virulence A (PavA) [76].
Pneumococci are also characterized by the expression of autolysins or cell wall
hydrolases that induce natural pneumococcal cell wall lysis, during the stationary phase
of growth and facilitate penicillin-induced lysis. The major autolysin, LytA, has been
shown to be important for pneumococcal virulence, partly by facilitating the secretion of
another key virulence factor – pneumolysin. In addition, LytA may be released to lyse
neighboring non-competent pneumococcal cells in a fratricidal manner [78]. By doing so,
it facilitates genetic exchange between naturally competent pneumococcal cells that
easily take up and incorporate DNA by homologous recombination. Furthermore,
autolysin facilitates the release of pneumococcal cell wall fragments and teichoic acids
that trigger inflammatory reactions and may interfere with phagocyte-mediated
elimination of live pneumococci [76, 79].
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Figure 1-5.

Streptococcus pneumoniae structure and virulence factors

Reprinted with permission from Nature Publishing Group. Kadioglu A, Weiser JN, Paton
JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host
respiratory colonization and disease. Nat Rev Microbiol 2008; 6:288-301 [76].
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Pneumolysin is another key virulence factor with diverse functions. When
secreted in high enough concentrations, it acts as a cholesterol-dependent, pore-forming
cytotoxin through oligomerization in the host cell membrane. At sub-lytic concentrations,
it can modulate target cell functions, such as inhibiting ciliary beating of respiratory
epithelial cells, and augmenting the synthesis of inflammatory cytokines. It may also
increase pneumococcal virulence by aggravating inflammatory responses during
pneumococcal infections [76]. Recently, it was shown that pneumolysin triggers IL-1beta
and IL-18 secretion through NLRP3 inflammasome activation, which probably mediates
host resistance against pneumococcal infections [80].
Moreover, pneumococci can secrete 3 neuraminidase proteins (NanA, NanB, and
NanC) that are important for pneumococcal in vivo growth. All strains express NanA,
most strains express NanB, and some strains express NanC [76, 81]. They cleave terminal
sialic acid residues from host cell surface glycoproteins or soluble host proteins, such as
lactoferrin. Thereby, they help reveal receptors for bacterial adherence on the host cell
surface. They can also secrete a zinc metalloprotease called IgA1 protease that targets
host mucosal IgA1 [76].
Pneumococcal Diseases
S. pneumoniae is a serious human bacterial pathogen found to be the most
common causative agent of pneumonia leading to hospitalization. Pneumococci can
spread locally from the nasopharynx to cause otitis media or sinusitis, or to the lungs,
probably by microaspiration, causing pneumonia. Beyond the lungs, pneumococci can
also invade epithelial barriers to the blood circulation, causing bacteremia, or severe
invasive infections, such as meningitis, with high mortality rates [82, 83].
During the transition of pneumococci from nasopharyngeal colonization to
invasive infections, they undergo phase variation and modulate the expression of several
virulence factors to become adapted to various microenvironments within the host.
Among these switches is capsule formation. Maximal capsule expression is critical for
systemic infections to help escape from various host humoral immunity and phagocytic
effectors. Therefore, pneumococci isolated from blood are highly encapsulated. In
contrast, during nasopharyngeal colonization, pneumococci have minimal capsule
expression to facilitate exposure of pneumococcal adhesins for better attachment to
respiratory epithelial cells [76].
Innate Immunity
Host immune responses during pneumococcal infections are multifaceted as
pneumococci are encountered by several lines of host defense, including innate nonspecific host defense lines, such as mucociliary clearance, complement activation,
neutrophils and macrophages. In addition, specific adaptive immunity is triggered,
generating protective humoral and cellular immunity against pneumococcal infections.
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Several key protective immune effectors were highlighted by observing hosts with
genetic deficiencies in certain immunity components and showing high susceptibility to
recurrent pneumococcal infections. Among them are the patients with deficiency in some
components of the complement system, such as C3, the central component of
complement activation pathways. Likewise, in old humans or aged mice, increased
susceptibility to pneumococcal pneumonia is associated with decreased inflammatory
immune responses, which may stem from the dysfunction of various TLRs in the lungs
[84, 85].
The complement system is a humoral component of innate immunity involving
more than 30 inactive serum and membrane-bound proteins. They are activated in a
cascade manner through 3 pathways and release effector molecules with diverse
functions. Complement activation pathways include the classical pathway, which is
activated by microbial antigen-antibody complexes or by acute phase proteins bound to
microbial surface, and the alternative pathway, which is constitutively turned on but to a
minor extent due to host cell-bound inhibitors. In contrast, activation of the alternative
pathway is amplified on foreign microbial surfaces due to absence of these inhibitors.
The third type is the lectin pathway, which is activated upon binding host mannosebinding lectin to carbohydrates on microbial surfaces. The activation outcomes by any
pathway comprise 3 major functions: deposition of certain cleaved components on
microbial surface functioning as opsonins, which enhance phagocytosis; chemotactic
functions for neutrophils and other inflammatory immune cells; and direct killing of the
microbe by membrane attack complexes which form pores in the microbial cell surface
[86].
During pneumococcal infections, the classical pathway is the dominant pathway
for complement activation and innate immunity against pneumococci [87]. It can be
activated after binding host natural IgM antibodies or acute phase proteins, such as C
reactive protein, to the pneumococcal surface [84, 88]. Strikingly, secreted pneumolysin
was found to activate the classical pathway in an antibody-independent manner.
However, this phenomenon was shown to contribute to pneumococcal virulence by
activating and consuming the complement away from the pneumococcal surface, thereby
preventing deposition of activated complement components on the pneumococcal surface
[89].
Respiratory epithelial cells are the first cells to detect pneumococcal colonization
and infection. They and other local immune cells express a wide range of PRRs. Diverse
PRRs are triggered during pneumococcal infections and signal activation and chemotaxis
of host immune cells by inducing the synthesis of different pro-inflammatory cytokines
and chemokines. Among them, TLR2, expressed on the host cell surface as heterodimers
with either TLR1 or TLR6, is activated by several pneumococcal-derived lipoproteins,
such as lipoteichoic acid. Experimental genetic deletion of TLR2 in mice increased
pneumococcal virulence by impairing efficient innate immune responses [84]. In
addition, some cytosolic PRRs, such as NOD1 and NOD2, are activated by the cell wall
of internalized pneumococci [90]. TLR9 is an intracellular endosomal PPR that can
recognize pneumococcal DNA which is released from spontaneously lysed pneumococci,
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and enhance bacterial phagocytosis [91] Additionally, pneumolysin augments the
induction of various inflammatory cytokines and can activate NLRP3, which is important
for rapid pulmonary clearance of pneumococci in mice [80].
Surfactant proteins are highly synthesized in the lungs to prevent the collapse of
alveoli. Among them, SP-D and SP-A have innate immune functions during pulmonary
pneumococcal infections by binding to pneumococci and enhancing their phagocytosis
[92].
Cellular innate immune effectors are crucial for early control of the replicating
pneumococci through phagocytosis and intracellular killing. Among them, resident AMs
are the critical first line of cellular innate immunity protecting lungs against invading
bacterial pathogens, including pneumococci [93]. Resident AMs are characterized by
high phagocytic capacity and play a key role in immunological homeostasis and
maintenance of the anti-inflammatory milieu in the lungs under steady-state conditions
[94, 95]. Artificial depletion of AMs in mice enhanced pneumococcal replication in the
lungs [93, 96].
Although pneumococci can resist complement-mediated opsonophagocytosis via
its polysaccharide capsule, the dynamic surface of resident AMs is characterized by a
diverse repertoire of surface non-opsonic receptors facilitating efficient phagocytosis of
encapsulated pneumococci. This repertoire includes class A scavenger receptors, such as
SR-AI/II and macrophage receptor with collagenous structure receptor (MARCO), as
well as C-type lectin mannose receptor, which can bind to the pneumococcal capsule,
thereby playing an important role in early pneumococcal clearance from murine lungs
[97, 98]. Recently, CD36, a scavenger receptor expressed on the surface of AMs and
respiratory epithelial cells, was shown to downregulate the early inflammatory response
while enhancing bacterial phagocytosis in an animal model of pneumococcal pneumonia
[99]. In addition, downregulation of MARCO receptor or impaired AM functions by TLR
desensitization after influenza infection may permit respiratory pneumococcal outgrowth
in animal models of secondary pneumococcal pneumonia [100, 101].
Inside AMs, phagocytosed pneumococci are destroyed by the conventional
intracellular killing mechanisms which involve lysosomal fusion and phagosome
maturation, accompanied by degradative action of various lysosomal enzymes and
bacterial cell damage by the NADPH oxidase-catalyzed oxidative burst. However, when
the intracellular killing capacity of AMs is exhausted, lysosomal permeabilization and
activation of cathepsin D take place leading to AM apoptosis with consequent killing of
internalized bacteria. [102].
In sub-clinical infections, efficient pulmonary clearance of pneumococci by
resident AMs is achieved preventing severe inflammatory sequelae. In contrast, when the
pneumococcal burden overwhelms the phagocytic capacity of resident AMs, secretion of
pro-inflammatory cytokines and chemokines is increased, mainly from the respiratory
epithelial cells, inducing recruitment of neutrophils, the second line of cellular innate
immunity against pneumococci [103]. Neutrophils or polymorph nuclear leukocytes are
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short-lived circulating immune cells and are the first cells to accumulate at sites of
pneumococcal infections or colonization. They become the dominant inflammatory
immune cells in the pneumonic lungs [104]. In addition, γδ T cells may play an important
role in the host defense against pulmonary pneumococcal infections by promoting
neutrophil influx in the lungs [105].
To kill pneumococci, neutrophils use a diverse armament involving phagocytosis
and intracellular bacterial killing by a combination of respiratory burst and non-oxidative
mechanisms. Activation of NADPH oxidase and myeloperoxidase, the primary arm of
the oxidative mechanism, leads to generation of various oxidizing species with potent
bactericidal activities. In addition, neutrophils are loaded with intracellular granules that
release several antimicrobial molecules, such as α-defensins, cathepsin G, lysozyme,
lactoferrin, and neutrophil elastase, upon fusion with the phagosome [106].
Neutrophils are also characterized by a unique mechanism of extracellular
bacterial killing. This mechanism involves the release of neutrophil DNA strands loaded
with antimicrobial molecules that form neutrophil extracellular traps (NETs) with potent
bactericidal activities. Although pneumococci are captured within NETs, they can escape
NET-mediated killing by secretion of bacterial endonuclease. In addition, the
pneumococcal capsule can decrease bacterial trapping in NETs. Likewise, increasing
positive charges over pneumococcal cell surface lipoteichoic acid enhances repulsion
from the positively charged NETs [107].
Besides their bacterial killing functions, neutrophils augment inflammatory
reactions causing bystander lung injury. The net outcome of the neutrophil influx during
pneumococcal pneumonia can be beneficial or deleterious, based on the virulence and
serotype of the pneumococci [108].
Adaptive Immunity
Adaptive immune effectors are crucial for developing protective immunity during
pneumococcal infections and conjugated polysaccharide capsule vaccination. B cells and
subsets of T cells mediate protective adaptive defense against pneumococci.
Discovery of antibody-mediated immunity against pneumococci was based on
very early studies in the 19th century on the protective functions of the serum isolated
from rabbits that were infected or immunized against pneumococcal infections [68]
Systemic antibodies specific against the pneumococcal polysaccharide capsule are the
most critical mediator for humoral protective immunity against invasive pneumococcal
infections. Differences in capsule structure led to production of antibodies with different
specificities which were the basis for serotyping and identification of more than 90
serotypes of pneumococci so far. Moreover, several pneumococcal surface proteins, lying
beneath or interspersed within the polysaccharide capsule, such as PspA and PsaA, are
immunogenic, inducing the production of pneumococcal-specific antibodies. These
antigens are conserved among most pneumococcal serotypes; thus their specific
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antibodies can provide broad protection. However, vaccines composed of individual
pneumococcal surface antigens are less potent than capsular polysaccharide vaccines, but
the potency can be synergized if they are combined [109].
There are two mechanisms for activating naïve B cells to secrete pneumococcalspecific antibodies: thymus-dependent and thymus-independent. Polysaccharide capsular
antigens stimulate terminally differentiated B cell proliferation by crosslinking specific B
cell receptors followed by secretion of specific antibodies and limited isotype switching
with the help of activating cytokines. It is considered a thymus-independent manner due
to the inability of capsular polysaccharides, except zwitterionic polysaccharides, to be
processed and presented on MHC class II for specific CD4+ T cell activation. In humans,
the isotypes of capsular-specific antibodies are restricted to IgM and IgG2, and to a lesser
extent IgG1, while they are IgM and IgG3 isotypes in mice [110]. This mechanism
induces a rapid increase in antibody titers, but it is transient due to the inability to
generate memory B cells. Therefore, repeated exposure to the capsule does not boost
specific antibody titers. Although they are elicited in a T cell-independent manner, some
studies showed a significant influence of CD4+ T cells on IgG responses to
pneumococcal capsular polysaccharides [111].
In contrast, pneumococcal surface proteins and other protein antigens can be
processed and presented for specific CD4+ Th cell activation and consequently elicit
thymus-dependent activation of specific B cells. Thus, B cells undergo clonal expansion
and differentiation into specific antibody-secreting plasma cells and memory B cells.
Specific antibody titers increase slowly but last longer and can be boosted by repeated
antigen exposures due to the presence of specific memory B cells. Likewise, the proteinconjugated pneumococcal capsular polysaccharide vaccines stimulate Th-dependent B
cell responses, as the co-expression of proteins with the capsular polysaccharides
stimulates CD4+ Th cells which activate capsular polysaccharide-specific B cell
responses associated with specific memory development, leading to a superior potency
over the pure polysaccharide vaccines [109, 110].
The protective functions of pneumococcal-specific antibodies are mainly
implemented through binding to the pneumococcal surface, which enhances
opsonophagocytosis and clearance of pneumococci through Fc receptors on phagocytes
or by classical activation of the complement system. The effectiveness of mucosal
pneumococcal-specific IgA is limited due to bacterial expression of a secreted zinc
metalloprotease, IgA1 protease that specifically targets human immunoglobulin A1
(IgA1), which constitutes more than 90% of the IgA in the human airway [76].
Additionally, antibody-independent CD4 + T cell-mediated immunity has been
shown to mediate protection against pneumococcal infections [112]. The importance of
CD4+ T cells in the protective immunity is clearly evident in HIV patients, as HIV
infection results in a 50-fold increased risk of pneumococcal infections that is inversely
related to CD4+ T cell count [113]. In animal studies using intranasal immunization with
killed pneumococcal whole cell vaccine, pneumococcal-specific CD4 + Th17 cells display
a significant role in the protection against pneumococcal colonization, which is mediated
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by IL-17A. Their protective role involves inducing recruitment of phagocytes, including
macrophages and neutrophils, which accelerate pneumococcal clearance [109, 114, 115].
The role of CD8+ T cells during pneumococcal infections and vaccination is
controversial. Animal studies using pneumococcus serotype 3 showed an essential role
for CD8 + T cells in antibody-mediated pulmonary protection, but not systemic immunity,
against pneumococcal infections [116, 117]. In contrast, another study suggested
suppressive activity of CD8 + T cells against capsular polysaccharide-specific antibody
responses in vaccinated mice [118]. Skewed Th17 cell responses were observed during
pulmonary pneumococcal infections in mice with genetic deletion of CD8 + T cells, which
may have deleterious inflammatory outcomes [117]. Therefore, the role of CD8 + T cell
responses may be partly justified through their regulatory influence on Th17 cell-induced
inflammatory activities.
Respiratory Bacterial Super-infections
Significance
Influenza and pneumonia caused the largest number of infectious disease-related
deaths in the United States throughout the 20th century [119]. Respiratory infections still
cause major public health problems with enormous clinical and socioeconomic burdens.
The rates of respiratory infections are higher than any other infectious disease worldwide
[120]. Generally, influenza infections are mild, and most influenza-associated morbidity
and mortality are not caused by the viral-induced damage itself. Instead, bacterial superinfections have been among the major reasons for the increased mortality during
influenza epidemics and pandemics [35].
René Laennec, who invented the stethoscope, was the first physician to describe
the “double” pneumonia as a common fatal complication during an 1803 influenza
epidemic in France. Throughout the recorded influenza epidemics and pandemics in the
modern history, secondary bacterial pneumonia (SBP) was a major complication in
severe and fatally-infected cases [121]. For example, the 1918 H1N1 influenza pandemic
was devastating, as it killed more than 30 million people worldwide, which is more than
three times the number of people killed during World War I [122]. Recently, it was
shown that more than 90% of autopsy lung tissues of the dead people were positive for
SBP, which was predominantly caused by S. pneumoniae [123]. Furthermore, the lethal
effects of SBP were also evident during later influenza pandemics in the antibiotic era, as
more than 50% of the fatal cases during the 1957 H2N2 and the 1968 H3N2 influenza
pandemics had SBP but with a significant remarkable contribution of Staphylococcus
aureus [123-125]. In addition, during the 2009 H1N1 influenza pandemic, about 25-50%
of fatal or severe cases had SBP [35, 36, 126]. In addition, more than 50% of children
infected with either pandemic 2009 H1N1 influenza or seasonal influenza had bacterial
co-infection, mainly by Staphylococcus aureus, and S. pneumoniae [127].
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Certain bacterial pathogens have been commonly isolated from patients with
secondary bacterial infections, such as S. pneumoniae, Staphylococcus aureus, and
Haemophilus influenzae [123, 128, 129]. Recent analysis of pooled human cases with
bacterial co-infections from 1950 to 2006 showed that pneumococcus was the most
common cause of bacterial co-infection with influenza. It accounted for about 40% and
16% of bacterial co-infections during pandemic and seasonal periods, respectively [128].
Given the significant frequency and effect of bacterial super-infections after
influenza, it is of paramount importance to study this respiratory viral-bacterial
synergism. Exploring key factors mediating this synergism will facilitate investigating
effective preventive and therapeutic approaches during seasonal and epidemic influenza
periods. In addition, it will allow better strategic preparedness for any future influenza
pandemics.
Mechanisms of Respiratory Viral-bacterial Synergism
Respiratory viral-bacterial synergism is a complex multifactorial phenomenon. It
involves several viral, bacterial, and host factors contributing to increased susceptibility
and the pathogenesis of bacterial super-infections following several types of respiratory
viral infections including influenza. However, the classical dogma explaining this
synergism has relied on the viral-induced damage in the respiratory epithelium exposing
more niches for bacterial adherence [35, 130]. This concept would be a major factor in
viral-bacterial synergism if the synergism was only observed with highly virulent viruses.
Yet, low pathogenic viruses have also been found to enhance susceptibility to bacterial
super-infections, as seen with seasonal influenza viruses [131, 132].
Four main mechanisms have been proposed to explain this synergism. These
mechanisms essentially describe factors underlying how primary viral infections establish
niches for secondary bacterial invaders and support their spread, virulence, and
outgrowth, while impairing host antibacterial defense lines (Figure 1-6).
The first category involves factors establishing foothold for secondary bacterial
pathogens which is the first step in successful bacterial infection. The breakdown of
respiratory epithelial barrier integrity, due to the death of influenza-infected cells lining
the airways, exposes extracellular matrix proteins providing more sites for bacterial
attachment. In addition, influenza NA activity cleaves sialic acid residues on the host
mucosal surface exposing more receptors for bacterial adherence. Increased viral NA
activity was shown to support SBP development [133]. This may also be explained by
facilitating viral spread deep in the lungs. Strikingly, released sialic acid residues, a good
carbon and energy source, are involved in several activities that support pneumococcal
biofilm formation in vitro and invasiveness in the lungs [35, 134]. Furthermore, plateletactivating factor receptor expression is upregulated during influenza infection which may
enhance pneumococcal invasiveness into the blood. However, it was shown to be
inessential for SBP progression [35, 135].
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Figure 1-6.

Respiratory viral-bacterial interactions

Reprinted with permission from PLOS. Bosch AA, Biesbroek G, Trzcinski K, Sanders
EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS
pathogens 2013; 9:e1003057 [136].
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The second category involves factors facilitating bacterial spread deep in the
lungs. Several respiratory viral infections, such as influenza and respiratory syncytial
virus infection, inhibit mucociliary beating. Thereby, they impair early mechanical
clearance of invading bacteria from the trachea, which promotes deep bacterial spread
within the lungs [137, 138]. Additionally, viruses with higher tropism to replicate deep
within the lungs, such as the 2009 pandemic H1N1 influenza virus, may establish niches
for secondary bacterial pathogens causing lower respiratory tract infections and SBP [35].
The third category proposes bidirectional synergistic interactions between
influenza viruses and the secondary bacterial pathogens, rather than the previous
mechanisms that involve unidirectional effects through the influenza viral pathogenicity
in the lungs. Indeed, specific pairings of viral and bacterial pathogens show successful
synergism in the lungs. In addition, different bacterial strains have remarkable differences
in their disease potential after primary influenza viral infection [139]. Bacterial virulence
factors may augment the pathogenesis of primary influenza virus infections. However,
only few of these factors are known [139]. For instance, proteases from Staphylococcus
aureus showed a synergistic effect on the infectivity of influenza viruses by activating
HA by cleavage, which increased co-infection pathogenicity [140]. Other examples of
bidirectional interactions include synergistic inflammatory responses during secondary
bacterial infections. Pathogenesis of primary influenza infections is believed to be mainly
due to inflammatory cytokine responses and host immunopathology. During bacterial coinfections, the host immunopathology is augmented at the site of infection. However, this
interaction is usually observed in a synergistic rather than an additive fashion, which
might be due to the remarkable increase in expression of certain PRRs in the lungs and
some circulating immune cells during influenza infections, such as TLR2, TLR3, and
TLR9 [141, 142]. Additionally, during the acute phase of the primary influenza infection,
the accumulated inflammatory immune cells would add to the total numbers of the
detecting system in the lungs. Thus, in addition to ongoing inflammatory responses
during influenza infection, secondary bacterial invaders elicit synergistic inflammatory
reactions after activating more PRRs and more immune cells. However, genetic deletions
of some TLRs, such as TLR2, did not prevent SBP development or lethal bacterial coinfections [143, 144].
The last category of the proposed mechanisms underlines the dysfunction of host
antibacterial immunity during primary influenza infections which leads to uncontrolled
bacterial outgrowth. Pathogenic bacteria invading terminal airways are encountered by
the host first line of innate defense composed of specialized highly phagocytic cells
within the alveolar airspaces – the resident AMs. Several studies of animal models
reported phagocytic dysfunction in AMs during influenza infections [145-148]. A more
recent study attributed this dysfunction to IFNγ-mediated downregulation of the
expression of a certain scavenger receptor, MARCO receptor, on the surface of AMs.
Thereby, their phagocytic capacity was decreased, and early pneumococcal clearance was
impaired during the resolution phase of sublethal influenza infection when adaptive
immune cells infiltrate the lungs with increased IFNγ production [101]. In addition, in
vitro incubation of murine macrophages with IFNγ may decrease macrophage expression
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levels of another scavenger receptor – the mannose receptor, and phagocytic functions
against certain bacterial pathogens [149, 150].
Viral PB1-F2 protein has also been implicated in viral-bacterial synergism and its
associated lung immunopathology. This viral protein is the product of an alternate open
reading frame of the PB1 viral gene segment in some influenza virus strains, with
variable expression in infected host cells leading to strain-specific pathogenicity [9]. It
has multifunctional properties, mainly contributed to by its pro-apoptotic and proinflammatory motifs [151]. Its expression leads to an enhanced inflammatory response
and lung immunopathology, contributing to the increased mortality in murine models of
SBP [152-154]. Furthermore, it has been suggested that it may induce the death of AMs,
thereby contributing to the impairment of antibacterial innate immunity during influenza
infections [155].
Impaired functions of murine NK cells during influenza infections have also been
implicated to contribute to the enhanced susceptibility to secondary Staphylococcal
infections, probably by decreasing the opsonophagocytic functions of AMs gated as
CD11bhi Gr1low CD11clow cells [156]. However, the role of NK cells in the pulmonary
antibacterial immunity is still controversial and needs to be fully examined with a variety
of bacterial pathogens [157, 158].
Neutrophils are considered the second line of innate immune cells, as they are
recruited to the lungs when resident AM phagocytic functions are impaired or
overwhelmed. Influenza A viruses may accelerate human neutrophil apoptosis in vitro
[159]. In addition, neutrophil dysfunction has been proposed to contribute to increased
bacterial super-infections after influenza infection [160]. However, the researchers found
that pneumococcal titers increased only with co-infection 6 days after influenza infection,
although neutrophil dysfunction was seen 3 and 6 days after influenza infection. In
addition, they depleted neutrophils using anti-GR1 RB6-8C5 monoclonal antibody,
which is a non-selective antibody that could also deplete monocytic cells expressing
Ly6C marker, thereby confounding the results [160]. Furthermore, they used a relatively
high dose of pneumococcus in their co-infection model, thus overwhelming AM
phagocytic capacity. Thus, they ended up examining neutrophil functions. Taken
together, the exact impact of influenza infections on neutrophil functions and whether
this effect really contributes to increased vulnerability to bacterial super-infections still
need to be carefully investigated.
Late after recovery from influenza infection, another mechanism of immune
dysfunction has been suggested by the findings of TLR desensitization in the lungs. This
mechanism relies on the enhancement of bacterial super-infections by impairing efficient
detection of bacterial pathogens by AMs. Thus, it leads to ineffective innate immune
responses against secondary bacterial infections [100]. However, this desensitization lasts
for several months, which is not clinically relevant to the timing window for successful
secondary bacterial infections observed in the first 2 weeks after influenza infection.
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In addition, the early upregulation of the type I IFN response during influenza
infection or the increased IL-10 production after the recovery of influenza infection has
been suggested to inhibit neutrophil influx which may contribute to the impaired
antibacterial innate defense. However, disrupting their signaling pathways provided only
partial or minimal resistance against secondary bacterial infections, which was linked to
increased neutrophil recruitment and/or functions [161, 162]. Furthermore, increased type
I IFN expression during influenza infection was suggested to suppress IL-17 secretion
from γδ T cells that may play important role in recruiting neutrophils during pulmonary
bacterial infections. Abrogating their signaling by genetic deletion of IFN alpha receptor
improved bacterial clearance and protected mice against SBP following influenza
infections [147, 163].
Efficient repair of influenza-induced epithelial damage is critical to restoring lung
homeostasis and functions. However, during bacterial co-infections, the repair process of
damaged epithelial cells is significantly impaired which may contribute to the lethality of
bacterial co-infections [144, 164].
In summary, several mechanisms have been proposed with varying levels of
evidence supporting their significant contribution to the enhanced susceptibility to
secondary bacterial infections following influenza and/or their increased lethality. The
current prophylactic and therapeutic measures against this serious medical problem are
targeting the infectious agents with either vaccinations or antimicrobial agents,
respectively. Indeed, much of these approaches succeeded in decreasing the significance
of respiratory secondary bacterial infections compared to the 1918 influenza pandemic
time or before. Nonetheless, in the influenza pandemic in 2009-2010, secondary bacterial
infections complicated more than one third of severe and fatal cases, even with
comprehensive diagnosis and treatment strategies. Many factors may have been involved
in this failure, among them is the reported increased emergence of resistant strains of
influenza viruses and secondary bacterial pathogens [165-167]. Furthermore, antiviral
therapy can only display effective prevention of SBP if administered early during primary
influenza infection by shortening the duration of viral shedding [35, 168]. Therefore,
investigating the effect of primary influenza infections on the host pulmonary
antibacterial immunity has become of paramount importance, as novel prophylactic or
therapeutic approaches based on immunomodulation would be more effective in breaking
this synergism by augmenting the host immunity against many secondary bacterial
pathogens simultaneously.
Lung-resident Macrophages
Lungs are part of the respiratory system with unique structure and very critical
functions for the human body through blood re-oxygenation at the terminal regions of the
lungs – the alveoli. With a very large surface area of about 70 m2 in adult humans and
continuous exposure to the external environment with a thin epithelial layer away from
the pulmonary capillaries, the alveoli look like a short step away from disaster [169].
Therefore, a complex immune regulatory network functions to maintain the lungs in a
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quiescent non-inflamed state. Critical players in this network are the lung-resident
macrophages.
There are two major subsets of lung-resident macrophages: AMs residing in the
alveolar lumen within the surfactant thin layer over the alveolar epithelial surface, and
interstitial macrophages (IMs) residing in the lung parenchymal tissue. Under steady state
conditions, AMs are the major hematopeotic cells in the alveolar airspaces. They were
first isolated via pulmonary alveolar lavage technique in 1961 [170]. Since that time,
several groups have studied the functions and ontology of pulmonary macrophages which
suggested developmental and functional differences between lung-resident AMs and IMs
[94, 171, 172]. IMs were suggested as precursors for resident AMs with intermediate
maturation stage, while AM ontogeny from circulating blood monocytes or by local
macrophage proliferation is still under debate [172-174]. Under inflammatory stimuli,
such as influenza infections, different exudate monocytes and macrophages are recruited
to the lungs which have different functional phenotypes and probably transcriptional
profiles from the lung-resident macrophages [53, 54].
Resident AMs play a pivotal role in the immune surveillance in the lungs.
Because of their high phagocytic capacity and strong microbicidal activities, they are
considered the first line of innate defense against inhaled particles and bacterial
pathogens [94, 171]. In addition, they display immunosuppressive activities and poor
antigen presenting capability in vitro and in vivo which may be critical to prevent
harmless environmental particulates from triggering detrimental inflammatory reactions
in the lungs [171, 175-179]. In contrast, IMs have lower phagocytic capacity but better
antigen presenting activities, as they express more surface MHC class II molecules and
can effectively induce T cell proliferation [94].
Therefore, investigating the impact of influenza infections on the lung-resident
macrophages in vivo is an attractive area, as it may elucidate part of the complex puzzle
of respiratory viral-bacterial synergism by explaining how influenza infection alters the
cellular innate immune defense in lungs and establishes a niche for the development of
SBP. This will also open avenues for novel immunomodulating prophylactic and
therapeutic interventions to prevent SBP during both pandemic and seasonal influenza
periods.
Scope and Objectives of Dissertation
Specific Aim 1: To Determine the Impact of Influenza Infection on the Lungresident Macrophages In Vivo
Sub-aim 1.1. To characterize and differentiate between subsets of lung-resident
macrophages and recruited macrophages using in vivo labeling approach.
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Sub-aim 1.2. To track dynamic changes of labeled lung-resident macrophages
during PR8 influenza infection.
Sub-aim 1.3. To determine if loss of resident alveolar macrophages during
influenza infection is due to increased cell death process.
Specific Aim 2: To Determine if Depletion of Resident Alveolar Macrophages
during Influenza Infection Contributes to Enhanced Susceptibility to Secondary
Pneumococcal Pneumonia
Sub-aim 2.1. To determine if early pneumococcal clearance within alveolar
airspaces is impaired during the depletion phase of resident alveolar macrophages after
influenza infection.
Sub-aim 2.2. To determine if the impaired early pneumococcal clearance
facilitates pneumococcal pneumonia development during the depletion phase of resident
alveolar macrophages after influenza infection.
Specific Aim 3: To Test if Expanding the Lung-resident Macrophage Pool Can
Protect Influenza-infected Mice against Secondary Pneumococcal Pneumonia
Sub-aim 3.1. To test if local GM-CSF treatment can replenish the alveolar
macrophage pool during influenza infection.
Sub-aim 3.2. To determine if the expanded pool of resident pulmonary
macrophages, by local GM-CSF treatment, can restore early pneumococcal clearance and
prevent secondary pneumococcal pneumonia in influenza-infected mice.
Specific Aim 4: To Test if Adjunctive Immunomodulator Therapy Can Improve
Outcomes during Bactericidal Antibiotic Treatment of Secondary Pneumococcal
Pneumonia
Sub-aim 4.1. To determine influence of the lung pneumococcal burden on the
lung immunopathology and mortality outcomes during ampicillin treatment of secondary
pneumococcal pneumonia.
Sub-aim 4.2. To test efficacy of corticosteroid therapy before or combined with
ampicillin treatment of mice with mild or severe secondary pneumococcal pneumonia.
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CHAPTER 2.

IMPACT OF INFLUENZA INFECTION ON THE LUNGRESIDENT MACROPHAGES IN VIVO 1
Introduction

Influenza and pneumonia are leading causes of morbidity and mortality in both
children and adults in the United States [180]. In developing countries, acute lower
respiratory infections are the leading cause of death in children younger than 5 years of
age [181]. Most influenza-related mortality is not due to the viral infection alone. Instead,
secondary bacterial pneumonia complicates many severe cases in influenza-infected hosts
[35]. This results in a tremendous economic burden due to increased hospitalizations,
medical costs, and indirect costs during both pandemic and inter-pandemic influenza
periods [123]. Complicating the picture, treatment of secondary bacterial pneumonia may
not be successful even in the antibiotics era. Globally increased rates of antimicrobial
resistance among many common respiratory bacterial pathogens and the mechanisms of
the drugs themselves can both complicate treatment and cure [165, 166, 182, 183]. The
continuous threat of a new influenza pandemic makes it crucial to understand how
influenza infection alters the host’s local innate immunity to the benefit of establishing
secondary bacterial infections.
Lungs are protected against bacterial infections by various components of innate
and adaptive immunity [44, 184]. Influenza-infected patients are vulnerable to bacterial
super-infections, suggesting defects in some or all of these resistance and clearance
mechanisms. Certain bacterial pathogens have been commonly isolated from patients
with secondary bacterial infections, such as S. pneumoniae [123, 128, 129]. Immunity to
S. pneumoniae is not completely understood at present in intact or compromised hosts.
Among host innate immune players, resident AMs are considered to be the most
prominent first line of defense against respiratory pneumococcal infections [93], through
their high phagocytic capacity [94-96].
Resident AMs therefore represent an intriguing target for study. However, the
strategies for differentiation of resident macrophage subsets in the airways and lung
tissues are insufficient to distinguish AMs from lung-resident IMs or inflammatory
monocytic cells invading the lung in response to infections. In some studies, AMs have
been putatively identified based on their surface immunophenotype as CD11c hi F4/80hi
cells. Indeed, CD11c and F4/80 surface markers are highly expressed on the AM surface,
but some inflammatory macrophages/ dendritic cells can express these markers as well
[185-187]. Thus, gating on these two markers only will not differentiate the various types
of cells during influenza infection, potentially leading to erroneous conclusions about the
absolute numbers of resident macrophages.

Adapted with permission from The American Association of Immunologists, Inc.
Ghoneim HE, Thomas PG, McCullers JA. Depletion of Alveolar Macrophages during
Influenza Infection Facilitates Bacterial Superinfections. J Immunol 2013; 191:1250-9.
1
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Using a novel in vivo labeling approach combined with extensive flow cytometric
analyses and confocal microscopic examination, we efficiently labeled and characterized
different subsets of lung-resident macrophages in lungs of naïve mice. We then
investigated the impact of sublethal influenza A virus infections on the two major subsets
of lung-resident macrophages – alveolar and interstitial macrophages – using a murine
model of sublethal influenza infections using different influenza virus strains.
Materials and Methods
Influenza Viruses
We used the St. Jude strain of mouse-adapted influenza virus A/Puerto Rico/8/34
(H1N1), referred to as “PR8”, as well as the human clinical isolate of the pandemic
influenza virus A/California/04/09 (H1N1) referred to as “pdm H1N1”. All viruses were
passaged once through Madin-Darby canine kidney (MDCK) cells, stocks were grown by
a single passage through eggs, and allantoic fluid was stored at −80°C. The viral titers of
the stocks were characterized via median tissue culture infective dose (TCID50) assay in
MDCK cells.
Mice
Six- to 8-week old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME)
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St.
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies
were approved by the Animal Care and Use Committee at St. Jude.
Infectious Model
Infectious agents were diluted in sterile phosphate buffered saline (PBS) and
administered intranasally in a volume of 100 μl (50 μl per nostril) to anesthetized mice
held in an upright position. In all experiments of influenza infection, PR8 influenza virus
was given at a dose of 25 doses infectious for 50% of tissue culture wells (TCID50) per
100 µl per mouse, which caused about 10% weight loss on day 7 after infection and no
mortality when given alone. The virus infectious dose in the pdm H1N1 experiment was
600 TCID50 per mouse, which caused morbidity and weight loss comparable to PR8
infection (data not shown).
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In Vivo Labeling of Lung-resident Macrophages
One hundred µl of 10 mM PKH26-PCL dye (Sigma-Aldrich, St. Louis, MO) was
intranasally administered into anesthetized mice 5 days before influenza infection, as
previously described [101].
Flow Cytometric Analysis of Immune Cells in Bronchoalveolar Lavage Fluid, Postlavage Lungs, and Mediastinal Lymph Nodes
Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc.,
Sandy, UT). Lungs were lavaged 4 times with 1 ml of cold sterile Hank’s buffered salt
solution (HBSS) supplemented with 0.1 mM ethylenediaminetetraacetic acid
(EDTA).The whole lungs after lavage or mediastinal lymph nodes were harvested and
physically homogenized by syringe plunger against a 40-µm cell strainer and washed in
FACS buffer consisting of HBSS, 0.1 mM EDTA, and 1% heat-inactivated fetal bovine
serum. Cell suspension of bronchoalveolar lavage fluid (BALF), post-lavage lung
homogenate, or mediastinal lymph nodes homogenate were centrifuged at 4°C, 350 × g
for 7 min, and the BALF supernatant was stored at –80°C. Flow cytometry (LSRII, and
LSRII Fortessa, Becton Dickinson, San Jose, CA) was performed on the cell pellets after
incubation with 75 μl of 1:200 dilution of Fc block (anti-mouse CD16/CD32, BD
Bioscience Inc., San Jose, CA) on ice for 10 min, followed by surface marker staining
with anti-mouse antibodies conjugated with different fluorescent probes: CD11c (eFluor
450), F4/80 (FITC), Ly6G (PerCp-Cy5.5), Ly6C (APC), and CD11b (APC-eFluor 780;
eBioscience Inc., San Diego, CA). The data were analyzed using FlowJo 8.8.6 (Tree Star,
Ashland, OR) where viable cells were gated from an FSC/SSC plot. First, neutrophils
(CD11bhi Ly6G hi) were gated out, then macrophages (CD11chi F4/80hi) were sub-gated
based on CD11b surface expression into AMs (CD11b -), IMs (CD11blow-int), and
recruited exudate macrophages (CD11b hi). Viable and non-viable cells were counted
before surface marker staining, and the percentage viability was counted via the trypan
blue exclusion method using a Cell Countess System (Invitrogen, Grand Island, NY). The
absolute numbers of different cell types were calculated based on the proportion of viable
events analyzed by flow cytometry as related to the total number of viable cells per
sample. Live/dead aqua dye was added during flow cytometric surface staining to
determine the total numbers of dead AMs and IMs. This dye binds to free amines after
penetrating the impaired cell membrane of dead cells. First, AMs and IMs were gated as
mentioned above but without prior gating for viable events based on forward scatter and
side scatter (FSC/SSC) dot plot. Live/dead aqua-positively stained AMs and IMs were
gated as dead cells, and their numbers were calculated based on the proportion of dead
events from the total events, analyzed by flow cytometry. Average mean fluorescence
intensity of PKH26-PCL was measured for different subsets of macrophages in the PE
channel.
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Confocal Laser Scanning Microscopy of PKH26-labeled Lungs
Five days after in vivo PKH26-PCL labeling of lung macrophages, euthanasia by
CO2 inhalation was performed, and the trachea was exposed and cannulated with a 24gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc., Sandy, UT).
Lungs were harvested after instillation of 1.2 ml of 4% freshly prepared formaldehyde
with PBS. Harvested lungs were fixed in 4% formaldehyde with PBS at room
temperature for 1 hour. Every lung was then washed with PBS and cut into 4 pieces
before mounting into PBS in 4 wells of Nunc Lab-Tek chambered cover glass (Thermo
Scientific, Rochester, NY) before microscopic examination. Fluorescence was visualized
with a Nikon Eclipse TE2000-E inverted microscope equipped with C2 confocal system
and a 40X/1.3NA numeric aperature oil objective (Nikon Instruments, Melville, NY).
Image collection and analysis were performed with Nikon NIS-Elements software
(Version 4.13).
Cytospin Slides Preparation
After harvesting BALF as described above, and before staining cells for flow
cytometry analysis, BALF cells were resuspended in PBS, cytospun (Thermo Scientific,
Ashville, NC) onto glass slides, and stained with Diff-Quick (Quik-Dip stain; Mercedes
Medical, Sarasota, FL). Neutrophils, monocytes/macrophages, and lymphocytes were
identified by morphology and images were taken from different representative fields of
stained macrophages under high power fields.
Statistical Analysis
Comparison of cell counts, and mean fluorescence intensity of PKH26-PCL in
BALF, and post-lavage lung homogenate between groups were compared using analysis
of variance (ANOVA). Mann-Whitney U test was used for pair-wise comparisons of
mean fluorescence intensity of PKH26-PCL between AMs and IMs in fixed lungs under
confocal microscopy, or comparisons of Ly6C surface expression between AMs, and
IMs, or recruited macrophages. A p-value of < 0.05 was considered significant for these
comparisons. Prism 4 for Windows (GraphPad Software, Inc., V 4.03) was used for all
statistical analyses.
Results
In Vivo Labeling of Lung-resident Macrophages Can Distinguish Alveolar
Macrophages from Interstitial Macrophages
Before examining any alterations in the lung-resident innate immune cells in
influenza-infected hosts, we determined critical techniques for the differential analysis of
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the heterogeneous population of macrophages in both alveolar airspaces and post-lavage
lung tissue. First, we refined a flow cytometry technique for gating resident macrophages
so that clear differentiation between different cells types could be accomplished. We used
the common markers CD11c hi and F4/80hi and added gating by another marker, CD11b
(β2-integrin). CD11b has been shown to be weakly expressed on AM cell surface [172,
188, 189] while highly expressed on granulocytes, exudate macrophages, monocytes, and
some dendritic cells [190-193]. Therefore, AMs are better gated as CD11c hi F4/80hi
CD11bdim in BALF as shown recently [189, 194]. This allowed differentiation in our flow
cytometric analysis of the two major subsets of lung-resident macrophages in mockinfected mice. Thus, AMs could be gated as CD11chi F4/80hi CD11b- and IMs as CD11chi
F4/80hi CD11blow-int in both BALF and post-lavage lung homogenate (Figure 2-1A).
To confirm our gating strategy for both subsets of lung-resident macrophages and
to differentiate them from recruited macrophages, we did in vivo labeling of lungresident macrophages before influenza infection using intranasally administered
PKH26-Phagocytic Cell Labeling (PKH26-PCL) dye. Both subsets of lung-resident
macrophages were intensely labeled by the dye, showing high means of the fluorescence
intensity of PKH26-PCL dye (MFI-PKH26). Nonetheless, significant differences in MFIPKH26 were observed between AMs and IMs in both BALF and post-lavage lung
homogenates, with IMs showing significantly lower MFI-PKH26 than AMs (Figure
2-1B). Additionally, selective labeling of lung-resident macrophages was confirmed by
confocal microscopy of fixed naïve PKH26-labeled lungs showing the same pattern of
difference in PKH26-MFI (Figure 2-2). These differences reflect the spatial and
functional differences between the two major subsets of lung-resident macrophages, with
IMs having less accessibility to the intranasally administered dye and lower phagocytic
capacity than AMs [94, 172, 195]. Thus, the in vivo labeling method confirmed the
validity of our flow cytometric gating strategy for the lung-resident macrophage subsets.
Influenza Virus Infection Depletes Alveolar Macrophages
To determine if influenza infection causes any alteration in the numbers of lungresident macrophages, we determined the percentages of lung-resident macrophages in
flow cytometric dot plots and calculated their absolute numbers. We infected BALB/c
female mice intranasally with the mouse-adapted H1N1 influenza virus strain A/Puerto
Rico8/34 (PR8) using a sublethal dose (25 TCID50 per 100 µl). Seven days after
influenza virus infection, more than 90% of the AM pool was depleted (Figure 2-3A). To
exclude the possibility that the observed depletion of AMs is unique to the use of a
mouse-adapted influenza virus strain (PR8), we examined changes in the AM pool size
using a sublethal dose of a human clinical influenza isolate from the 2009 influenza
pandemic, the A/California/04/09 H1N1 strain (pdm H1N1). We found that AMs were
significantly depleted within 7 days after pdm H1N1 infection to levels comparable to
PR8 infection (Figure 2-3B). Furthermore, we also tested the impact of sublethal
influenza B virus infection in vivo, and we found significant depletion of resident AMs
on days 3 and 5 after infection (data not shown).
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Figure 2-1.

Differentiation between lung-resident macrophages subsets

(A) Flow cytometry dot plots show the gating strategy of resident alveolar macrophages
(AMs, R4 gate) and interstitial macrophages (IMs, R5 gate) in BALF (top plots) and
post-lavage lungs (bottom plots) of mock-infected mice. (B) In vivo labeling of lungresident macrophages using PKH26-PCL dye before influenza infection can distinguish
AMs (solid red bars) from IMs (solid black bars) based on the mean fluorescence
intensity (MFI) of PKH26-PCL dye in both BALF and post-lavage lungs (n = 4).
***P < 0.001 by Tukey's multiple comparison test (ANOVA). The bar graphs show the
average ± SD.
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Figure 2-2. Fluorescence microscopic examination of PKH26-labeled naive lungs
confirms selective in vivo labeling of lung-resident macrophages
(A) Photomicrographs show that both AMs (arrow) and IMs (asterisk) are selectively
labeled by PKH26-PCL dye and emit red PKH26 fluorescence. Green autofuorescence
can be detected from AMs, IMs, and elastin and collagen fibers. (B) AMs have
significantly higher PKH26-MFI and autofluorescence compared with that of IMs
measured from 3 different fields. Images were obtained by a Nikon Eclipse TE2000-E
microscope (n=3).
**P < 0.01 by Mann-Whitney U test. The bar graphs show the average ± SD.
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Figure 2-3. Lung-resident alveolar macrophages are depleted during influenza
virus infections
Absolute numbers of AMs in bronchoalveolar lavage fluid (solid bars) and post-lavage
lungs (open bars) of PR8-infected (A), or 2009 pandemic H1N1-infected mice (B),
analyzed 7 days after influenza infection, are significantly lower than in mock-infected
(naive) mice (n ≥ 5, in each group of mock-infected or influenza-infected mice).
***P < 0.001 by Mann-Whitney U test, compared with mock-infected (naïve) mice. The
bar graphs show the average ± SEM.
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Tracking of Lung-resident Macrophage Dynamic Changes during Influenza
Infection
To track depletion kinetics of AMs and changes of the IM pool size during
influenza infection, we again did in vivo labeling of lung-resident macrophages followed
by sublethal PR8 influenza infection and studied different time points in the first 2 weeks
after influenza virus infection. We found that AMs were significantly depleted in the
alveolar airspaces shortly after PR8 infection starting on the first day p.i. (Figure 2-4A).
Considering that some AMs may not be completely harvested in BALF and still adhere to
the respiratory tract lining, we also analyzed post-lavage lungs and found that higher
numbers of AMs remained in the post-lavage lung homogenate. These remaining AMs
were significantly depleted starting 3 days p.i. compared with those in mock-infected
mice (Figure 2-4B). Consequently, 3 days after PR8 influenza infection was identified as
the earliest time point of significant whole lung AM depletion. The AM pool was
partially replenished 9 days p.i. (in BALF only), while complete replenishment appeared
11 days p.i. (Figure 2-4A and B). Conversely, the IM pool was not significantly depleted
during the course of influenza infection; however, it was expanded at later time points
(Figure 2-4A and B).
By tracking dynamic changes in MFI-PKH26 of AMs and IMs after PR8
influenza infection, we observed that MFI-PKH26 of AMs significantly decreased during
the full replenishment period starting 11 days p.i (Figure 2-5A and B). In contrast, MFIPKH26 of IMs decreased shortly after influenza infection without significant changes in
their absolute numbers observed in the post-lavage lungs in the first week of infection
(Figure 2-4B and Figure 2-5B). However, in the second week, the IM pool significantly
expanded with a significant increase in their absolute numbers harvested from BALF
(Figure 2-4A). This may suggest partial depletion of IMs pool which can be quickly
restored through their rapid proliferative capacity.
Validity and Stability of the In Vivo Labeling Approach to Distinguish Different
Subsets of Pulmonary Macrophages during the Tracking Period
To confirm the validity of the tracking process of lung-resident macrophages
during the course of influenza infection, dynamic changes in their MFI-PKH26 were
measured. At any time point after influenza infection, AMs showed the highest MFIPKH26 compared to IMs or recruited exudates macrophages (Figure 2-6A and B),
despite the observed decrease in MFI-PKH26 of AMs during their full replenishment
period starting 11 days p.i. (Figure 2-5A and B). Thus, it confirms our flow cytometric
gating strategy that differentiates between resident AMs and IMs, and newly recruited
exudate macrophages.
We did further characterization of the different macrophage subsets in the lungs
during influenza infection based on their surface expression levels of Ly6C antigen that
can be used to differentiate between resident and recruited inflammatory macrophage
subsets, in addition to their maturation stages [191, 192]. We found that resident AMs did
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Figure 2-4. Tracking of lung-resident macrophage dynamic changes during
influenza infection
Absolute numbers of resident AMs and IMs in BALF (A) and post-lavage lungs (B) of
PR8-infected mice harvested 1, 3, 5, 7, 9, 11, and 14 days p.i (n ≥ 4).
*P < 0.05,**P < 0.01,***P < 0.001 by Dunnett's multiple comparison test (ANOVA),
compared with mock-infected (naïve) mice. Data are expressed as the average ± SD.
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Figure 2-5. Dynamic changes of the mean fluorescence intensity of PKH26-PCL
of the lung-resident macrophages during influenza infection
Tracking the changes in MFI (mean fluorescence intensity) of PKH26-PCL dye of
resident AMs and IMs in BALF (A) and post-lavage lungs (B) at different time points
during influenza infection (n ≥ 4).
*P < 0.05,**P < 0.01,***P < 0.001 by Dunnett's multiple comparison test (ANOVA),
compared with influenza-infected mice 1 day p.i. Data are expressed as the average ± SD.
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Figure 2-6. Differential mean fluorescence intensity of PKH26-PCL dye of
different pulmonary macrophage subsets during influenza infection
Comparisons of MFI-PKH26 (mean fluorescence intensity of PKH26-PCL) of different
pulmonary macrophage subsets, including resident AMs, IMs, and recruited macrophages
in BALF (A) and post-lavage lungs (B) during the course of influenza infection (n ≥ 4).
*P < 0.05,**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with
AMs at each time point. The bar graphs show the average ± SD.
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not express surface Ly6C, while resident IMs express intermediate levels, reflecting their
intermediate stage of maturation and supporting the previous studies suggesting IMs as
precursors for AMs [172, 196]. In contrast, the recruited exudates macrophages with
CD11bhigh phenotype showed significantly high expression levels of Ly6C (Figure 2-7).
We also determined the stability of PKH26-PCL dye in vivo in the mock-infected
lungs, to exclude the possibility that these observed changes in PKH26-MFI of lungresident macrophages after influenza infection were not due to instability of the dye, but
rather due to changes in resident macrophage pool size via maturation of unlabeled
macrophages. PKH26-PCL dye demonstrated efficient labeling and stability inside the
lung-resident macrophages for at least 14 days after mock-infection (i.e. 19 days after
labeling), thereby covering the tracking period during which we did the kinetics analyses
(Figure 2-8).
Ontogeny of the Replenished Pool of Alveolar Macrophages after Influenza
Infection
To determine origin of the replenished AM pool during the resolution phase of
influenza infection, we sub-gated AMs based on the fluorescence intensity of
PKH26-PCL dye into PKH26 high, PKH26int, and PKH26- subsets. We then measured the
frequencies of these 3 sub-populations as percentages of total numbers of resident AMs.
Surprisingly, the PKH26- subset did not virtually contribute to the replenishment of
resident AM pool, implying a neglected contribution of the recruited, non-labeled,
macrophages in resident AM homeostasis. Instead, more than 75% of AM pool after full
replenishment was composed of PKH26 high subset (on days 11 and 14 p.i), suggesting
their probable origin from PKH26 high IMs after differentiation and maturation into the
resident AM phenotype (Figure 2-9).
The remaining portion of the replenished AMs consists of PKH26 int subset and
represents about 25% of total replenished AMs (Figure 2-9). Its intermediate level of
PKH26-PCL fluorescence intensity suggests that it developed through proliferation of the
remaining PKH26-labeled AMs or PKH26-labeled IMs followed by maturation into the
AM phenotype.
Influenza Infection Induces Cell Death of Alveolar Macrophages
To determine whether AM depletion is due to a cell death process, we measured
the total numbers of dead AM cells during PR8 infection using a cell viability dye
(live/dead aqua). The total numbers of dead AMs were significantly higher in both BALF
and post-lavage lungs of influenza-infected mice than in mock-infected mice (Figure
2-10A). In contrast, there was no significant difference between the total numbers of dead
IMs in influenza-infected and mock-infected mice (Figure 2-10B). To determine the type
of AM cell death process, we examined alveolar macrophages for any morphologic
changes associated with influenza infection. Diff-Quick -stained cytospin slides of BALF
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Figure 2-7. Differential surface expression of Ly6C marker on different
pulmonary macrophage subsets
Ly6C-MFI are compared at different time points after influenza infection.
**P < 0.01, ***P < 0.001 by Mann-Whitney U test, where AMs are compared with IMs,
and IMs are compared with recruited MФ at each time point (n ≥ 4). The bar graphs show
the average ± SD.
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Figure 2-8. Fluorescence intensity of PKH26-PCL dye is stable in lung-resident
macrophages for 2 weeks after mock infection
% PKH26-MFI values are calculated as percentages of the average PKH26-MFI of AMs
on day 3 after PBS administration (n ≥ 4).
*P < 0.05 by Dunnett's multiple comparison test (ANOVA), compared with % PKH26MFI of AMs on day 3 after PBS. The bar graphs show the average ± SD.
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Figure 2-9. Ontogeny of the replenished alveolar macrophage pool during
influenza infection
Alveolar macrophages were sub-gated based on degree of PKH26-PCL labeling into
PKH26high, PKH26int, and PKH26- subsets. Then frequencies of each sub-population were
measured as percentages of total numbers of AMs at different time points after PR8
influenza infection (n = 6-8).
The bar graphs show the average ± SD.
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Figure 2-10. Influenza infection induces significant alveolar macrophage cell death
Total numbers of dead AMs (A) and IMs (B) are calculated during influenza infection.
(C) Cytospin of Diff quick-stained BALF cells from mock-infected and PR8-infected
mice 3 days p.i at magnification × 500.
*P < 0.05,**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with
mock-infected naive mice. The bar graphs show the average ± SD.
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cells harvested from influenza-infected mice 3 days p.i. showed many macrophages with
cellular damage manifestations. They were characterized by distorted nuclei and more
vacuoles in cytoplasm than in mock-infected mice (Figure 2-10C). This suggests that
cell death was due to a secondary necrotic process.
To determine if AMs were lost due to recruitment to the lung-draining lymph
nodes, we examined the mediastinal lymph node 7 days after PR8 influenza infection and
did not observe significant recruitment of PKH26-labeled AMs to it (data not shown).
Discussion
In this chapter, we determined the impact of sublethal influenza infections on the
two major subsets of murine lung-resident macrophages in vivo. Dramatic depletion of
resident AMs, but not IMs, takes place for a certain period during influenza infection, in
association with a remarkable increase in the dead AM cell numbers early after infection.
This depletion was not only observed during infection by a mouse-adapted H1N1
influenza A virus strain (PR8), but it was also shown during sublethal infections using
human clinical isolates of the 2009 pandemic H1N1 influenza A virus and influenza B
virus.
Tracking the PKH26-labeled AMs during PR8 influenza infection revealed a
temporary depletion process from day 3 to day 9 after infection under the infection
settings and with the mouse strain which we used. About 70% of AMs were depleted
after 3 days, reaching a nadir (> 90% depletion) 7 days after PR8 influenza infection.
This matches the previously established boundaries for maximum synergism in the
secondary bacterial infection model [197], which parallel the typical order and timing of
infections in humans [198]. Interestingly, in another influenza infection model using a
different strain, percentage of resident AMs – gated as CD11chigh Mac-1 - - decreased on
day 3 p.i [199], which is consistent with our findings. However, the authors did not show
the absolute numbers of these cells.
Efficient replenishment of the AM pool then took place during the resolution
phase of influenza infection. We investigated the ontogeny of the replenished AMs, and
found that their pool was mainly recovered through local proliferation and differentiation
of IMs into AM phenotype. Strikingly, our novel findings were also recently suggested
by another research group that used a genetic approach to track genetically labeled lungresident macrophages during PR8 influenza infection. They showed significant lungresident macrophage cytoablation on day 6 after influenza infection and suggested that
these macrophages could repopulate later, mainly by local proliferation [173].
We highlighted the critical requirement for using approaches that could efficiently
distinguish between different lung-resident macrophage subsets – AMs and IMs, and
differentiate them from the inflammatory macrophages and DCs recruited during lung
infections. Indeed, the PKH26-PCL in vivo labeling approach combined with the flow
cytometric analyses and confocal microscopic examination could efficiently label and
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characterize different subsets of lung-resident macrophages in the lungs of naïve mice, in
addition to differentiating them from recruited unlabeled immune cells. Therefore, one
observation stemming from our findings is that examination of lung-resident
macrophages in the setting of influenza infection should be cautiously performed. During
influenza infection, diverse chemokines are upregulated in lungs, activating an influx of
heterogeneous populations of innate immune cells, such as monocytes, inflammatory
macrophages, and monocyte-derived dendritic cells. The dynamic changes in the
phagocyte populations in influenza-infected lungs require critical methods to distinguish
resident macrophages from recruited ones. Based on the surface phenotype of lungresident macrophages in naïve mice, we used an extensive gating strategy to analyze and
differentiate resident and recruited macrophages. Thus, AMs were gated as CD11chi
F4/80hi CD11b-, while IMs and recruited macrophages were gated as CD11chi F4/80 hi
CD11blow-int and CD11chi F4/80hi CD11bhigh respectively. Further characterization showed
the ability of the Ly6C marker to differentiate between resident and recruited phagocytes
and their maturation stage in influenza-infected lungs. Ly6C antigen is expressed by
circulating blood monocytes and macrophages, which can be recruited to tissues under
inflammation conditions [191]. However, Ly6C expression is down-regulated during
differentiation of blood monocytes or macrophages into tissue resident macrophages after
migration to tissue. Therefore, it can be added as a suitable marker to differentiate
macrophage subsets and their stages of maturation into tissue resident phenotype [192].
Moreover, in vivo labeling of lung-resident macrophages was done to validate our gating
strategy and to distinguish between resident AMs and recruited macrophages. The
PKH26-PCL dye used to label macrophages forms fluorescent microparticles, which can
be taken up by the resident phagocytes in the lungs. The dye remains stable
intracelullarly for more than 21 days [101], and emits high fluorescence intensity for at
least 19 days based on our findings.
Furthermore, monitoring changes of MFI-PKH26 for lung-resident macrophages
reflected the dynamic changes in their absolute numbers during influenza infection. For
instance, expansion of the AM pool during the recovery phase was accompanied by
significant decrease in their MFI-PKH26. Nevertheless, the AM population showed the
highest MFI-PKH26 at various times during the first 2 weeks after influenza infection.
Thereby, the significantly high MFI-PKH26 of AMs during their replenishment phase in
addition to the high percentages of PKH26 high sub-populations implied that the AM pool
was mainly replenished via local proliferation and differentiation of the PKH26-labeled
IMs into an AM surface phenotype, rather than maturation of PKH26-unlabeled recruited
blood macrophages. In contrast, the quick drop in MFI-PKH26 of IMs in the first week
after influenza infection, without apparent changes in their absolute cell numbers,
suggests that influenza infection may induce partial depletion of the IM pool. However,
this partial depletion can be quickly re-compensated by the proliferative capacity of IMs,
maturation of the recruited macrophages, or both [94, 172].
Several investigators, who used animal models of influenza infections, couldn’t
identify depletion of resident AMs during influenza infections because of some
limitations in their analysis. Mostly they used gating strategies not sufficient to
distinguish between resident AMs, IMs, and recruited exudate macrophages. For
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example, gating for a single marker like F4/80 antigen or macrophage-specific esterase
staining of macrophages isolated from BAL fluid during influenza infection is targeting
mixed populations of resident and recruited macrophages whose total cell numbers
increase during infection [200]. In addition, although the same in vivo labeling method
was used before, AM depletion couldn’t be identified during influenza [101]. Based on
their analysis, they gated AMs as CD11c + PKH26+ which may be mixed with IMs. They
analyzed AM numbers on day 9 after influenza infection in BAL fluid only. Based on our
model, we showed certain period for AM depletion from day 3 to day 9 after influenza
infection. Analyzing depletion events by monitoring AMs at a single time point (day 9
p.i) during influenza infection is inconclusive. Furthermore, analyzing cells in BAL fluid
may cause us to miss AMs that remain adherent in the lungs after lavage leading to the
underestimation of the resident AM pool size during the comparison between influenzainfected and mock-infected mice. Likewise, in another study the authors did not show
AM depletion because of missing CD11b marker in their AM gating, as well as
harvesting only BAL fluid for kinetics analysis [185]. Taken together, missing an
important marker that distinguishes between different lung-resident macrophage subsets
and recruited monocytic cells or using BAL fluid only for analyzing resident AMs may
lead to erroneous conclusions regarding their kinetics during infections.
In summary, sublethal influenza infection induces transient depletion of the
resident AMs, which temporally parallels the period of the increased clinical
susceptibility to SBP following influenza infections in humans. These findings led us to
propose a novel mechanism of influenza-mediated immunosuppression in the lungs.
However, whether this proposed mechanism contributes to the increased vulnerability to
SBP still needs to be experimentally tested.
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CHAPTER 3. DEPLETION OF RESIDENT ALVEOLAR MACROPHAGES
DURING INFLUENZA INFECTION CONTRIBUTES TO ENHANCED
SUSCEPTIBILITY TO BACTERIAL PNEUMONIA2
Introduction
Bacterial super-infections are among the common complications during influenza
infections. Specifically, SBP has been found complicating significant percentages of
severe cases and deaths during periods of influenza outbreaks and seasonal influenza.
Furthermore, SBP remarkably contributed to the increased mortality during several
influenza pandemics even after antibiotics discovery and their wide routine use. For
instance, in the last 2009 influenza pandemic, 25%-50% of severe or fatal cases had SBP
[35, 36, 126].
Mechanisms of the increased predisposition to SBP following influenza infections
have been investigated for a long time [35, 147, 201]. Several studies have been
performed to explain the synergistic interactions between influenza viruses and secondary
bacterial pathogens. Previous studies of viral-bacterial synergism in our laboratory have
focused on influenza virus virulence factors and their damaging effects on respiratory
tract epithelial cells, together with synergistic inflammatory lung injury during coinfection [35, 129]. However, our findings in Chapter 2 provided insights of a novel
mechanism underlying the increased permissiveness to SBP through influenza-induced
loss of the most critical innate immune cells in the lungs – the resident AMs.
Lung-resident AMs are considered the most important cells of the first line of
innate defense against respiratory pneumococcal infections [93] due to their high
phagocytic capacity [94-96]. We reasoned that early escape from the first line of defense
in the lungs could have profound effects on immunity to a variety of pathogens, including
secondary bacterial invaders. Enhanced bacterial growth and replication through this
mechanism could allow enhanced expression of virulence factors and the resulting
inflammatory response. Therefore, we sought to determine if the resident AM depletion
during influenza infection contributes to the enhanced susceptibility to SBP.
Additionally, we tested an immunomodulation intervention to prevent this defect in the
antibacterial immunity by expanding the lung-resident macrophage pool during influenza
infection so that it might protect influenza-infected mice against SBP.
We used standard murine influenza virus infection and co-infection models [202],
in which BALB/c female mice are infected intranasally by a sublethal dose of influenza
A virus – this primary infection may then be followed by a sublethal dose of S.
pneumoniae at different time points after influenza infection. We demonstrated that
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resident AM depletion impairs early bacterial clearance, supporting development of SBP
during the AM depletion phase. These data have implications for understanding virusinduced host immune suppression that may lead to improved prevention and treatment of
primary or secondary infections in the lungs.
Materials and Methods
Infectious Agents
For influenza infections, we used PR8 influenza virus and prepared the infectious
dose from the same stocks as described previously (page 29).
For secondary bacterial infections, we used the clinical human isolate of S.
pneumoniae A66.1, a type 3 encapsulated strain. It was engineered to express luciferase
(Kevin Francis and Jun Yu, Xenogen Corporation, Alameda, CA). Pneumococci were
grown in Todd Hewitt broth (Difco Laboratories, Detroit, MI) to an OD620 of
approximately 0.4 and then frozen at −80ºC mixed 2:1 with 5% sterile glycerol. The titers
of the frozen stocks were quantitated on tryptic soy agar (Difco Laboratories, Detroit,
MI) supplemented with 3% v/v sheep erythrocytes (blood agar). In all instances, the
infectious dose administered was confirmed by serial dilution and plating of the bacterial
suspension on blood agar plates.
Mice
Six- to 8-week-old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME)
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St.
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies
were approved by the Animal Care and Use Committee at St. Jude.
Infectious Model
Infectious agents were diluted in sterile PBS and administered intranasally in a
volume of 100 μl (50 μl per nostril) to anesthetized mice held in an upright position. In
all experiments of influenza infection, PR8 influenza virus was given at a dose of 25
TCID50 per 100 µl per mouse, which did not cause mortality when given alone. In coinfection experiments, PR8 infection was followed at the specified time point by
pneumococcal challenge with 200 colony forming units (CFUs) per mouse. Infected mice
were weighed and assessed daily for illness and mortality for 7 days after pneumococcal
challenge.
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Imaging of Live Mice
Mice were then imaged for 60 seconds using an IVIS CCD camera (Caliper Life
Sciences, Alameda, CA) daily after pneumococcal challenge to monitor in vivo
pneumococcal pneumonia development. Total photon emission from selected and defined
areas within the images of each mouse was quantified using Living Image software
(Caliper Life Sciences, Alameda, CA) as described previously [152, 203, 204] and
expressed as the flux of relative light units per minute. Pneumonia was defined as visible
bioluminescence within the thorax and detection of a flux of > 11,000 relative light units
per minute.
Flow Cytometric Analysis of Immune Cells in BALF and Post-lavage Lungs
Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc.,
Sandy, UT). Lungs were lavaged 4 times with 1 ml of cold sterile HBSS supplemented
with 0.1 mM EDTA. The whole lungs after lavage were harvested and processed, in
addition to BALF cell suspension, for surface marker staining as described previously
(page 30). AMs and IMs were gated as described previously (page 30). Viable and nonviable cells were counted before surface marker staining, and the percentage viability was
counted via the trypan blue exclusion method using a Cell Countess System (Invitrogen,
Grand Island, NY). The absolute numbers of different cell types were calculated based on
the proportion of viable events analyzed by flow cytometry as related to the total number
of viable cells per sample.
Determination of Early Pneumococcal Clearance
Early pneumococcal clearance was determined by measuring the pneumococcal
count remaining within alveolar airspaces. Briefly, mice were euthanized by CO 2
inhalation 3 h after pneumococcal inoculation. BALF was harvested using sterile HBSS
supplemented with 0.1 mM EDTA (lavage by 1 ml twice), and then half the BALF was
spread on blood agar plates supplemented with 0.4 mg kanamycin/ml blood agar to select
for kanamycin-resistant luciferase-expressing pneumococci [203] and incubated at 37°C
overnight.
Local GM-CSF Treatment Regimen
We treated anesthetized mice intranasally with 25 µg of recombinant mouse GMCSF (Granulocyte/Monocyte-Colony Stimulating Factor, Invitrogen, Grand Island, NY)
in 100 µl of sterile PBS on days –1 and +1 before and after PR8 infection. We treated
control mice with vehicle (PBS) only.
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Statistical Analysis
Comparison of survival and pneumonia development between groups of mice was
done with the log-rank chi-squared test on the Kaplan-Meier survival data. Comparison
of bacterial titers, and cell counts in BALF, and post-lavage lung homogenate between
groups were compared using analysis of variance (ANOVA). Comparison of weight loss
between groups of mice was done using Mann-Whitney U test for pair-wise comparisons.
A p-value of < 0.05 was considered significant for these comparisons. Prism 4 for
Windows (GraphPad Software, Inc., V 4.03) was used for all statistical analyses.
Results
Influenza Infection Enhances Susceptibility to Secondary Pneumococcal Pneumonia
Influenza-mediated death of AMs is likely to have significant effects on primary
and secondary immunity. To explore one potential defect, we studied the permissiveness
of influenza-infected hosts to secondary respiratory bacterial infections. We first infected
BALB/c female mice intranasally with PR8 influenza virus using a sublethal dose (25
TCID50). Influenza-infected mice showed mild morbidity manifested as loss of about
10% of their original body weight within 7 days after influenza infection (Figure 3-1A).
At that time point, we induced secondary bacterial infection via intranasal administration
of a small inoculum (200 CFUs) of the serotype 3 clinical isolate of S. pneumoniae,
A66.1. Influenza-infected mice showed high susceptibility to secondary pneumococcal
infection with a significant increase in morbidity and continuous body weight loss
(Figure 3-1A). All co-infected mice died within 3 to 5 days after pneumococcal
inoculation (Figure 3-1B). In contrast, all single influenza- or single pneumococcusinfected mice recovered quickly with no mortality (Figure 3-1A and B). To determine
whether the co-infected mice died due to pneumococcal pneumonia, we monitored
pneumococcal growth in vivo through bioluminescent imaging of the lungs [203]. Only
co-infected mice developed serious pneumococcal infections; pneumonia occurred within
48 h after pneumococcal inoculation (Figure 3-1C). Likewise, sublethal influenza B
virus infection enhanced the susceptibility to develop lethal secondary pneumococcal
pneumonia, if influenza-infected mice get secondarily infected with 200 CFUs of
pneumococci at time points with significant AM depletion (data not shown).
AM Depletion during Influenza Infection Impairs Early Pneumococcal Clearance
To determine whether the observed depletion of the AM pool contributes to
enhanced susceptibility to secondary pneumococcal infection in influenza-infected hosts,
AM phagocytic function was assessed in vivo by measuring early pneumococcal
clearance with or without influenza infection. First, we determined the earliest time point
at which a small pneumococcal inoculum (200 CFUs) could be efficiently cleared within
the alveolar airspaces of naive mice. Pneumococcal early clearance was tested at different
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Figure 3-1.

Murine influenza-pneumococcal co-infection model

Body weight loss (A) and survival rate (B) of single pneumococcal-infected (PBS and S.
pneumoniae (St. pn.), n = 6), single influenza-infected (influenza and PBS, n = 8), and
co-infected (influenza and S. pneumoniae, n = 9) mice with 7 days interval between two
doses in each group. (C) Thorax bioluminescence of luciferase-expressing A66.1
pneumococcus from 3 representative co-infected mice showing development of
pneumococcal pneumonia. Images were taken 48 h after secondary bacterial challenge
using 200 CFUs of pneumococcus on day 7 after influenza infection. (D) Pneumococcal
titers harvested 3 h after bacterial inoculation (inoculum of 200 or more CFUs) from
alveolar airspaces of mock-infected and influenza-infected mice 7 days p.i. are shown as
percentage of inoculum.
*** P < 0.001 by Mann-Whitney U test, compared at each time point with single
influenza-infected mice group (Panel A), by log-rank test on the Kaplan Meier survival
data (Panel B), or by Dunnett's multiple comparison test (ANOVA), compared with
mock-infected mice (Panel D). Data represent the average ± SD.

52

time points (1, 2, 3, and 4 h) after bacterial inoculation. Complete pneumococcal
clearance was observed within 3 h after pneumococcal inoculation in naïve mice (data
not shown). Then, we tested the ability of influenza-infected lungs to clear this small dose
of pneumococcus (200 CFUs) at this early time point. This experiment demonstrated that
early pneumococcal clearance was significantly impaired in the alveolar airspaces of
influenza-infected mice compared with mock-infected controls. Mock-infected mice
could efficiently clear more than 95% of up to 50-fold higher doses of pneumococcus,
while influenza virus-infected mice were unable to clear the basal inoculum (Figure
3-1D).
Influenza-infected Mice Demonstrate Increased Susceptibility to Secondary
Pneumococcal Pneumonia during the AM Depletion Phase
To determine whether AM depletion during influenza infection correlates with the
susceptibility to secondary pneumococcal infection, we examined the early
pneumococcal clearance at different time points after influenza infection. Early
pneumococcal clearance was significantly impaired during PR8 infection from 3 until 9
days p.i. (Figure 3-2A). This period of early pneumococcal clearance impairment closely
mirrors the phase of the AM pool depletion observed during PR8 infection (Figure 2-4A
and B). Later, after the full replenishment of the AM pool, the impaired early
pneumococcal clearance was restored starting from day 11 p.i (Figure 3-2A).
To determine whether the impaired early pneumococcal clearance during
influenza infection enhances susceptibility to secondary pneumococcal pneumonia
development, we monitored mouse lungs via bioluminescence imaging 24 h after
bacterial inoculation. Among the influenza-infected mice, 100% developed secondary
pneumococcal pneumonia when they were secondarily infected by pneumococcus 3, 5, or
7 days after influenza infection. In contrast, all influenza-infected mice that were
secondarily infected either 1 days or 14 days p.i. cleared the bacterial dose efficiently and
did not develop secondary pneumococcal pneumonia (Figure 3-2B). Secondary
pneumococcal pneumonia development was less frequent in influenza-infected mice that
were secondarily infected by pneumococcus on 9 or 11 days p.i., with only 60% or 40%
of pneumonic mice, respectively (Figure 3-2B). As expected in this model, all coinfected mice that developed secondary pneumococcal pneumonia died within few days
due to bacterial pneumonia (Figure 3-2C).
Local GM-CSF Treatment Expands the Lung-resident Macrophage Pool in
Influenza-infected Mice
To restore the early bacterial clearance efficiency that was impaired during the
AM depletion phase, we tested local recombinant GM-CSF treatment as a means to
accelerate replenishment of the depleted AM pool in influenza-infected mice.
Recombinant GM-CSF was intranasally administered in 2 doses on days –1 and +1
before and after PR8 infection (Figure 3-3A). First, we analyzed the effect of this
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Figure 3-2. Successful co-infection synergism during the AM depletion phase in
influenza-infected mice
(A) Pneumococcal CFUs, as percentages of inocula, harvested 3 h after bacterial
inoculation (inoculum of 200 CFUs) from the alveolar airspaces of mock-infected and
influenza-infected mice 1, 3, 5, 7, 9, 11, and 14 days p.i. Secondary pneumococcal
pneumonia development (B) and mortality (C) are manifested in influenza-infected mice
that are secondarily pneumococcal-infected during the AM depletion phase (D.1 group; n
= 5, D.3 group, n = 6; D.5 group, n = 4; D.7 group, n = 10; D.9 group, n = 5; D.11 group,
n = 5; and D.14 group, n = 5 ).
*P < 0.05, ** P < 0.01, ***P < 0.001 by Dunnett's multiple comparison test (ANOVA),
compared with mock-infected mice (Panel A), or compared with Day 1 or Day 14 coinfection groups by log-rank test on the Kaplan Meier survival data (Panel B and C).
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Figure 3-3. Local GM-CSF treatment expands the lung-resident macrophage pool
in influenza-infected mice
(A) Diagram showing local GM-CSF treatment regimen, where recombinant GM-CSF
was intranasally administered into PR8-infected mice on days –1 and +1 before and after
infection. Then BALF and post-lavage lungs were harvested for analysis of lung-resident
macrophages. (B) The absolute numbers of AMs and IMs increased in GM-CSF-treated
influenza-infected mice analyzed 3 days p.i (n ≥ 4).
*P < 0.05,***P < 0.001 by Dunnett's multiple comparison test (ANOVA), compared
with mock-treated mock-infected mice. The bar graphs show the average ± SD.
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GM-CSF treatment regimen on the size of the AM and IM pools. Local GM-CSF
treatment in influenza-infected mice resulted in a significant expansion of the IM pool
with partial replenishment of the AM pool (Figure 3-3B).
Local GM-CSF Treatment Decreases the Susceptibility to Secondary Pneumococcal
Pneumonia Following Influenza
To evaluate the efficacy of local GM-CSF treatment in the co-infection model,
pneumococcus was administered 3 days after PR8 infection into GM-CSF-treated and
mock-treated mice groups (Figure 3-4A). Local GM-CSF treatment led to better early
pneumococcal clearance in influenza-infected mice than in mock-treated mock-infected
mice. Conversely, early pneumococcal clearance remained impaired in mock-treated,
influenza-infected mice (Figure 3-4B). Interestingly, some of the GM-CSF-treated
influenza-infected mice could efficiently clear the bacterial inoculum, while others could
not. Next, we tested the ability of local GM-CSF treatment to prevent secondary
pneumococcal pneumonia development after bacterial inoculation 3 days p.i. Local GMCSF treatment protected more than 50% of co-infected mice against secondary
pneumococcal pneumonia. Meanwhile, all mock-treated co-infected mice developed
pneumococcal pneumonia (Figure 3-4C).
Discussion
Influenza is well known to increase susceptibility to secondary bacterial
infections, such as SBP. The increased permissiveness of influenza-infected lungs to
pneumococcal outgrowth suggests a defect in the host innate immune defenses that
establishes a niche for bacterial infections. In this Chapter, we examined a novel
mechanism of influenza-mediated immune suppression, which is the depletion of resident
AMs. The resulting immune defect is likely to have pleiotropic effects on primary and
secondary immunity. We examined one potential effect; bacterial escape from early
innate immunity contributing to enhanced vulnerability to SBP. Resident AMs are
essential for early bacterial clearance and protection against bacterial infections [93, 101].
We found that early clearance of small pneumococcal inocula was significantly impaired
during the AM depletion phase. The impaired early bacterial clearance correlated with
successful progression to SBP.
In most studies of primary or secondary pneumococcal pneumonia in animal
models, AM-mediated protection has not been rigorously studied [101, 147, 205]. This
appears mainly to be because of the use of high doses of pneumococcus (≥ 1×10 5 CFUs)
to overwhelm the phagocytic capacity of resident AMs and induce a robust and
reproducible pneumonia. Under these settings, neutrophil influx coupled with the
development of early adaptive response in the form of serotype-specific antibody was
found in these models to be important for host protection against primary pneumococcal
pneumonia [84, 104, 161]. However, in the perhaps more physiologically relevant setting
of a relatively small dose of pneumococcus (200 CFUs) after sublethal mild influenza
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Figure 3-4. Local GM-CSF treatment decreases the susceptibility to secondary
pneumococcal pneumonia following influenza
(A) Diagram showing local recombinant GM-CSF treatment into PR8-infected mice on
days –1 and +1 before and after infection, followed by intranasal administration of 200
CFUs of pneumococcus on day 3. GM-CSF treatment improved early pneumococcal
clearance within the alveolar airspaces (B) and secondary pneumococcal pneumonia
development (C) compared with mock-treated co-infected mice (GM-CSF-treated group,
n = 9, PBS-treated group, n = 4).
**P < 0.01 by Dunnett's multiple comparison test (ANOVA), compared with mocktreated mock-infected mice (Panel B), or *P < 0.05 by log-rank test on the Kaplan Meier
survival data, compared with mock-treated co-infected mice (Panel C).
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infection, we could demonstrate a strong effect mediated by AMs. This low bacterial
inoculum successfully caused lethal secondary pneumococcal pneumonia within 48 -72 h
after bacterial inoculation, pneumonia that was mainly dependent on an absence of the
resident AMs.
GM-CSF is a cytokine with diverse functions and is known to be critical for
effective innate immunity in lungs. It regulates AM differentiation and activation [188,
206], enhances proliferation of resident pulmonary macrophages [173, 192], and expands
the pool of resident AMs [207]. It also has an important role in pulmonary surfactant
homeostasis [208]. Recent studies showed that GM-CSF over expression in lungs has
prophylactic activity against lethal influenza and pneumococcal pneumonias [207, 209,
210]. We found that local recombinant GM-CSF treatment in influenza-infected mice
induced significant expansion of the IM pool. In addition, absolute numbers of AMs
increased under this treatment regimen in influenza-infected mice. This increase was less
than that of IMs, possibly because they were analyzed at an earlier time point (3 days p.i).
Our data are consistent with previous studies showing that GM-CSF enhances the
proliferation capacity of lung-resident macrophages and maturation of AMs. Considering
the higher proliferative capacity of IMs over AMs, our short treatment regimen could
significantly expand the pool of IMs more than AMs. As a result of the partial
replenishment of the AM pool with pulmonary GM-CSF treatment, influenza-infected
mice had partial restoration of efficient early pneumococcal clearance. Furthermore, they
manifested improved protection against secondary pneumococcal pneumonia. Although
pulmonary GM-CSF treatment has some drawbacks such as inflammatory activity [211]
that can render its use in humans problematic by exacerbating inflammatory lung injury,
the results of our study are promising. They suggest that strategies seeking to balance the
protective AM replenishment effects and the adverse effect of exuberant inflammation
induction via combining an adjunctive anti-inflammatory therapy with GM-CSF
treatment may be successful.
Overall, these findings suggest a novel mechanism of influenza-mediated immune
suppression that resulted in increased permissiveness of influenza-infected hosts to SBP.
Resident AM depletion during influenza infection establishes a niche for secondary
pneumococcal infection by altering early cellular innate immunity in the lungs, thereby
allowing pneumococcal outgrowth causing lethal pneumococcal pneumonia. The precise
functional characterization of this novel finding can change the way researchers look at
the alteration of pulmonary cellular innate immunity during sublethal influenza
infections. There are likely to be important effects on immunity beyond the bacterial
escape studied here. Furthermore, these findings open avenues for novel
immunomodulating therapeutic interventions to prevent respiratory bacterial superinfections by quick replenishment of the critical innate immune effectors during both
pandemic and seasonal influenza.
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CHAPTER 4. ADJUNCTIVE IMMUNOMODULATOR THERAPY IMPROVES
MORTALITY DURING ANTIBIOTIC TREATMENT OF SECONDARY
PNEUMOCOCCAL PNEUMONIA
Introduction
Globally, pneumonia is the leading killer of children outside of the neonatal
period [181]. In addition, there has been little change in mortality due to respiratory tract
infections for more than five decades [119, 120]. SBP is a common complication of
influenza, and outcomes are worse in co-infections than in uncomplicated cases [35,
212]. In the 1918 influenza pandemic, the majority of deaths were complicated by SBP,
and S. pneumoniae was the predominant pathogen [123]. However, the advent of
antibiotic therapy in 1940s and the widespread use of effective pneumococcal vaccines in
the developed world decreased the frequency of pneumococcal diseases over the last
century. Nonetheless, S. pneumoniae continues to be the leading bacterial cause of
community-acquired pneumonia (CAP) and SBP [213]. For example, during the 2009
H1N1 influenza pandemic, 25% to 50% of severe or fatal cases were complicated by
SBP, mostly with S. pneumoniae and Staphylococcus aureus [35, 126, 214].
These severe outcomes including mortality are seen in patients with SBP despite
appropriate antimicrobial treatment [212, 215]. Although globally increased rates of
antimicrobial resistance among common respiratory bacterial pathogens are a concern
[165, 166], the mechanism of killing utilized by standard antibiotics also appears to affect
treatment outcomes [183, 204]. Ampicillin is considered the first line therapy for
bacterial pneumonia in hospitalized children, including those co-infected with influenza
[216]. In a murine model of SBP following influenza, treatment with ampicillin was
shown to induce robust inflammatory lung injury [202]. This poor treatment outcome,
despite its efficient bactericidal activity, was attributed to rapid bacterial cell wall lysis
and the release of copious amounts of bacterial PAMPs, including cell wall fragments,
potentiating the inflammatory response in the co-infected lungs [204]. Trials in adults
have demonstrated an improved cure rate for inpatient CAP treatment with either
fluoroquinolone antibiotics or combination therapy with a β-lactam and a macrolide
[217]. Our mouse studies suggest that, along with broadened coverage of atypical
pathogens, the addition of the macrolide to the recommended treatment regimen reduces
the inflammatory response by decreasing the massive influx of neutrophils and
accompanying tissue damage characteristic of SBP [204]. However, treatment with
antibiotics alone appears to still be sub-optimal in some patients and in these mouse
models.
Due to their potent anti-inflammatory and diverse immunomodulatory activities,
corticosteroids have been widely used to treat many inflammatory and immune diseases
[218, 219]. However, the clinical use of corticosteroids as an adjunctive therapy for
treating pneumonia has been controversial. Some randomized controlled clinical trials
suggest beneficial activity in treating CAP with a significant reduction in the length of
hospital stay [220, 221] or a decrease in mortality of patients with septic shock [222].
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However, others have shown no benefit or harmful outcomes [223, 224]. Based on these
data and expert opinion, the World Health Organization (WHO) discouraged
corticosteroid treatment during the 2009 influenza pandemic [225]. Collectively, there is
not currently strong evidence in the literature for recommending adjunctive corticosteroid
therapy. Nevertheless, steroids are often used in clinical practice, particularly in severe
cases with acute lung injury, suggesting a need for further study [226-228].
We hypothesized that adjunctive corticosteroid therapy would improve the poor
outcomes associated with antibiotic treatment of SBP following influenza infection
through modulation of inflammatory responses. We tested our hypothesis using a wellestablished murine co-infection model in which we could monitor the progression of SBP
in vivo [229]. To analyze the relationship between disease severity and outcomes, we
categorized co-infected mice based on the lung bacterial load at the onset of antibiotic
treatment to control for its impact on different treatment outcomes. We report here that
dexamethasone therapy administered during the inflammatory period of severe SBP has a
beneficial effect on outcomes. Early therapy, during primary influenza, is not beneficial
and may enhance the infection by interfering with immune responses to the virus.
Additionally, we tested the efficacy of a novel immunomodulator drug, 2,3diacetyloxybenzoic acid (DABA). DABA was designed as a pro-drug of 2,3dihydroxybenzoic acid (DHBA) to increase its lipophilicity and thus increase its
intracellular delivery [230]. DHBA is an old drug known by its strong iron chelation
activity for a long time [231]. It was also identified as a siderophore secreted from some
bacterial pathogens to facilitate iron uptake in the iron limited environment [232]. DHBA
was shown to decrease vancomycin-induced nephrotoxicity in rats, which was assumed
to be mediated through decreasing free hydroxyl radical formation [233].
However, DHBA showed limited efficacy in treating animal models of acute lung
injury and sepsis, whereas its pro-drug, DABA, was shown to attenuate the endotoxininduced acute lung injury in two separate animal models. Early systemic treatment by
DABA before and after endotoxin administration could significantly decrease lung
microvascular permeability [230]. Therefore, we sought to test if adjunctive DABA
therapy would also prevent the increased lung immunopathology associated with
antibiotic treatment of SBP. We also tested the efficacy of DABA with early
administration during primary influenza infection.
Materials and Methods
Infectious Agents
PR8 influenza virus and S. pneumoniae A66.1, a type 3 encapsulated strain, were
prepared and used for murine co-infections as described previously (pages 29 and 49).
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Mice
Six- to 8-week-old female BALB/c mice (Jackson Laboratory, Bar Harbor, ME)
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St.
Jude. Animals were given general anesthesia that consisted of 2.5% inhaled isoflurane
(Baxter Healthcare Corporation, Deerfield, IL) prior to all interventions, and all studies
were approved by the Animal Care and Use Committee at St. Jude.
Co-infection Model
Infectious agents were diluted in sterile PBS and administered intranasally in a
volume of 100 μl (50 μl per nostril) to anesthetized mice held in an upright position. For
primary influenza infection, influenza virus was given at a dose of 25 TCID50 per 100 µl
per mouse, which caused about 10% weight loss on day 7 p.i (post infection) with no
mortality when given alone. To engender SBP, influenza infection was followed on day 7
p.i by bacterial challenge with 200 CFUs of pneumococcus per mouse. Infected mice
were weighed and assessed daily for illness and mortality for 7 days after pneumococcal
challenge; based on preliminary studies in this model and animal care considerations, any
mouse losing more than 26% of its starting body weight was euthanized and considered
to have died on that day.
Imaging and Ampicillin Treatment of Live Co-infected Mice
Mice were imaged for 60 seconds using an IVIS CCD camera (Caliper Life
Sciences, Alameda, CA) daily after pneumococcal challenge to monitor in vivo
pneumococcal pneumonia development. Total photon emission from selected and defined
areas within the images of each mouse was quantified using Living Image software
(Caliper Life Sciences, Alameda, CA) as described previously [152, 203, 204], and
expressed as the flux of relative light units per minute. Pneumonia was defined as visible
bioluminescence within the thorax and detection of a flux of > 11,000 relative light units
per minute (RLU/min) [229]. Based on previous studies that classified detection stage of
SBP into early and late detection [152, 204], we assigned mild pneumonia to mice
showing thorax bioluminescence and flux of more than 11,000 but less than 90,000
RLU/min, while severe pneumonia was defined for mice with flux of more than 90,000
RLU/min. Once SBP was detected, ampicillin (Sigma-Aldrich) was given i.p. as 200
mg/kg/daily in two divided doses every 12 hours for 5 days.
Flow Cytometric Analysis of Immune Cells in BALF and Post-lavage Lungs
Following euthanasia by CO2 inhalation, the trachea was exposed and cannulated
with a 24-gauge plastic catheter (Becton Dickinson Infusion Therapy Systems, Inc.,
Sandy, UT). Lungs were lavaged, harvested, and homogenized as described previously
(page 30). Then, cell suspensions of BALF and post-lavage lung homogenate were
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centrifuged at 4°C, 350 × g for 7 min. BALF and lung homogenate supernatants were
stored at –80°C. Flow cytometry (LSRII, and LSRII Fortessa, Becton Dickinson, San
Jose, CA) was performed on the cell pellets after incubation with Fc block (anti-mouse
CD16/CD32, BD Bioscience Inc., San Jose, CAio), followed by surface marker staining
with cocktail of anti-mouse antibodies conjugated with different fluorescent probes,
including CD11c (eFluor 450), F4/80 (FITC), Ly6G (PerCp-Cy5.5), and CD11b (APCeFluor 780; eBioscience Inc., San Diego, CA), or CD3 (FITC), CD4 (APC), and CD8a
(eFluor 450 or APC-eFluor 780; eBioscience Inc., San Diego, CA). FlowJo 8.8.6 (Tree
Star, Ashland, OR) was used for data analysis, where viable cells were gated from an
FSC/SSC plot, and then neutrophils were gated as (CD11b hi Ly6G hi CD11clo F4/80lo). T
cells were gated as CD3 + SSC low-int, followed by sub-gating of CD4+ CD8- and CD8+
CD4- T cells subsets. Total viable cells were counted and absolute numbers of different
cell types were calculated as described previously (page 30).
Dexamethasone Treatment Regimen
Dexamethasone sodium phosphate injection solution (4 mg/ml; APP
Pharmaceuticals, Schaumburg, IL) was diluted by sterile PBS solution to 0.5 mg/ml. In
combined treatment experiments, dexamethasone dose (2.5 mg/kg/day) or vehicle (PBS)
was given i.p. once daily 2-3 hours after ampicillin injection for 5 days as adjunctive
therapy. In early treatment experiments, dexamethasone or PBS was given i.p. once daily
starting from day 3 until day 13 after influenza infection.
2,3-Diacetyloxybenzoic Acid Treatment Regimen
DABA was a kind gift from Dr. Ze-Qi Xu (Advanced Life Sciences Co.,
Woodridge, IL). DABA injection solution (25 mg/ml) was prepared freshly according to
the manufacturer’s instructions. Briefly, 50 mg of the drug was dissolved in 0.5 ml of
8.4% sodium bicarbonate injection, USP. Then, 1.5 ml of sterile distilled water was
added followed by vortex and sonication until the drug powder gets completely
dissolved, then the solution was filter sterilized. The injection solution was kept at 4°C
and was used within 1-2 days. Mice were i.p injected with DABA in the same dose as
used before for treating acute lung injury (150 mg/kg/day) [230], but following the same
regimen as dexamethasone.
Measurement of Viral Titers
Influenza viral titers were measured in the stored post-lavage lung homogenate
supernatants by TCID50 assay in MDCK cells.
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Measurement of Total Protein and Albumin Levels in BALF Supernatant
BALF supernatant aliquots were thawed and total proteins levels were measured
spectrophotometrically using a NanoDrop 2000 Spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE). To measure albumin levels, BALF supernatant samples
were diluted in sterile PBS, then albumin concentrations were measured using an ELISA
kit (USCN Life Science Inc, Houston, TX).
Statistical Analysis
Comparison of survival between groups of mice was done with the log-rank chisquared test on the Kaplan-Meier survival data. Means of relative bioluminescence units
per minute were compared between groups using analysis of variance (ANOVA).
Comparison of weight loss, immune cells numbers, or viral titers between groups of mice
was done using Mann-Whitney U test for pair-wise comparisons. A p-value of < 0.05
was considered significant for these comparisons. Prism 4 for Windows (GraphPad
Software, Inc., V 4.03) was used for all statistical analyses.
Results
Ampicillin Treatment during Secondary Pneumococcal Pneumonia Fails to Rescue
Mice Despite Viral and Bacterial Clearance
To engender SBP, naïve BALB/c mice were intranasally infected by a sublethal
dose of influenza virus, followed by a small inoculum of pneumococcus on day 7 after
influenza infection (Figure 4-1A). Within 48 h after bacterial inoculation, co-infected
mice developed SBP that could be detected in vivo by bioluminescence imaging. Without
treatment all co-infected mice succumbed to bacterial pneumonia within a few days
(Figure 4-1B). To confirm the poor efficacy of a standard antibiotic treatment in rescuing
mice with SBP, I started ampicillin treatment upon pneumonia detection via
bioluminescence (Figure 4-1A and C). As seen previously [202, 204, 234], ampicillin
could only rescue about 40% of pneumonic mice (Figure 1B), despite rapid declines in
bacterial burden within 12 h after the first dose of ampicillin (Figure 4-1C and D). Viral
titers were undetectable in the alveolar airspaces 24 h after the first ampicillin dose (data
not shown).
Differential Outcomes Depend on the Severity of Secondary Pneumococcal
Pneumonia at the Onset of Antibiotic Treatment
To determine if the severity of SBP at the onset of antibiotic treatment affects
treatment outcomes, we classified the severity of pneumonic mice prior to antibiotic
treatment into mild or severe pneumonia. This classification was based on the
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Figure 4-1.

Ampicillin treatment of secondary pneumococcal pneumonia

(A) Diagram showing the co-infection model where mice are intranasally infected by
influenza virus (PR8) followed by secondary pneumococcal challenge (S. pneumoniae) 7
days later. The ampicillin treatment regimen is started upon secondary pneumococcal
pneumonia detection (often on day 9 p.i). (B) Survival rates of co-infected mice either
untreated (n = 6) or after ampicillin treatment (n = 17). (C) Two representative
bioluminescent images of co-infected mice showing development of secondary
pneumococcal pneumonia (0 h), and effective pneumococcal killing 12 h after first
ampicillin dose. (D) Significant reduction of throax bioluminescence flux from mice with
secondary pneumococcal pneumonia (n = 8) after first doses of ampicillin treatment to
levels comparable to naïve mice (n = 6, measurements expressed as relative luminescence
units (RLU)/min).
*P < 0.05 by log-rank test on the Kaplan–Meier survival data, compared with untreated
group (Panel B). ***P < 0.001 by ANOVA test, compared with all other groups (Panel
D). The bar graph shows the average ± SD.
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pneumococcal load in co-infected lungs, as monitored through bioluminescence imaging
as defined in the methods (Figure 4-2A).
Ampicillin treatment was associated with disparate mortality outcomes in mice
with different degrees of pneumonia at the onset of treatment (Figure 4-2B). All
ampicillin-treated mice with severe pneumonia succumbed to pneumonia in a similar
pattern to that of the untreated group. In contrast, more than 60% of ampicillin-treated
mice with mild pneumonia were rescued (Figure 4-2B). These differential mortality
outcomes after ampicillin treatment were not due to lack of ampicillin bactericidal
activity in mice with severe pneumonia; the first ampicillin dose demonstrated in vivo
efficacy with rapid bacterial killing, reflected by the significant decrease in
bioluminescence signals to levels comparable to uninfected mice, in a similar pattern to
ampicillin-treated mice with mild pneumonia (Figure 4-2C).
However, differential accumulation of neutrophils was observed within the
alveolar airspaces of mildly and severely pneumonic mice 26 h after the first ampicillin
dose (Figure 4-3A). Interestingly, ampicillin treatment of mice with severe SBP induced
significantly greater accumulation of neutrophils than in the untreated mice with SBP at
the same time point (day 10 after influenza infection) (Figure 4-3A). Furthermore,
significantly higher total proteins levels were detected in the BALF supernatant of
ampicillin-treated mice with severe pneumonia (Figure 4-3B).
Adjunctive Dexamethasone Treatment Rescues Ampicillin-treated Mice with Severe
Secondary Pneumococcal Pneumonia
Since treatment by ampicillin alone failed to rescue mice with severe pneumonia,
despite its efficient bactericidal activity, we hypothesized that an anti-inflammatory agent
could dampen the associated inflammatory responses and improve outcomes. Adjunctive
dexamethasone therapy significantly improved the survival rate, rescuing about 70% of
mice with severe pneumonia (Figure 4-4A). Mice with mild pneumonia also
demonstrated a modest increase in survival that was not statistically significant after
adjunctive dexamethasone treatment, but suffered morbidity reflected by significant delay
in regaining their body weight as compared to the PBS and ampicillin-treated control
group (Figure 4-4B). Improved outcomes with combined therapy were associated with
significantly decreased neutrophil accumulation after the second dose (Figure 4-5A) and
significantly reduced serum albumin leakage into alveolar airspaces after the first dose
(Figure 4-5B).
Early Dexamethasone Treatment Leads to Loss of Its Protective Activity
To test if dexamethasone administration early after influenza infection can
enhance its protective activity and increase survival of ampicillin-treated pneumonic
mice, we started dexamethasone or PBS treatment 3 days after influenza infection and
continued thereafter until day 13 p.i using the same co-infection model. As before,
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Figure 4-2. Differential mortality outcomes depend on the severity of secondary
pneumococcal pneumonia at the onset of antibiotic treatment
(A) Representative images showing bioluminescence measurements from two different
co-infected mice with mild or severe secondary pneumococcal pneumonia. Images were
taken 48 h after secondary pneumococcal challenge and prior to ampicillin treatment. (B)
Survival rates of co-infected mice with mild (Amp-M, n = 10) or severe (Amp-S, n = 7)
secondary pneumococcal pneumonia treated with ampicillin. (C) Significant reduction in
thorax bioluminescence flux from co-infected mice with either mild or severe secondary
pneumococcal pneumonia after first doses of ampicillin treatment (n = 10) to levels
comparable to naïve mice (n = 6).
** P < 0.01 by log-rank test on the Kaplan–Meier survival data, compared with Amp-S
group (Panel B), *** P < 0.001 by ANOVA test, compared with all other groups (Panel
C). The bar graphs show the average ± SD.
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Figure 4-3. Differential lung immunopathology depends on the severity of
secondary pneumococcal pneumonia at the onset of antibiotic treatment
(A) Absolute numbers of neutrophils in BALF of mock-infected (naïve, white-filled, n =
12), untreated co-infected mice on day 10 after influenza infection (black-filled, n = 15),
or ampicillin-treated mice with mild (light gray-filled, n = 7) or severe (dark gray-filled, n
= 6) secondary pneumococcal pneumonia 3 days after bacterial challenge (i.e. 26 h after
first ampicillin dose). (B) Total proteins levels in BALF supernatant of untreated coinfected mice on day 10 after influenza infection (black-filled, n = 5), ampicillin-treated
mice with mild (light gray-filled, n = 7) or severe (dark gray-filled, n = 9) pneumonia,
measured 26 h after first ampicillin dose.
* P < 0.05, *** P < 0.001 by ANOVA test, compared with all other groups (Panel A and
B). The bar graphs show the average ± SD.
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Figure 4-4. Adjunctive dexamethasone treatment rescues ampicillin-treated mice
with severe secondary pneumococcal pneumonia
Survival rates and body weight loss curves of ampicillin-treated mice with either severe
(Panel A, n ≥ 7) or mild (Panel B, n ≥ 9) secondary pneumococcal pneumonia with
adjunctive dexamethasone or mock (PBS) therapy.
*P < 0.05,** P < 0.01 compared with adjunctive PBS therapy group by log-rank test on
the Kaplan–Meier survival data (Panel A), or Mann-Whitney U test for body weight loss
curve (Panel B). Data are expressed as the average ± SEM.
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Figure 4-5. Adjunctive dexamethasone therapy improves lung inflammation and
pulmonary vascular permeability in mice with severe secondary pneumococcal
pneumonia
(A) Absolute numbers of neutrophils within alveolar airspaces of mice with severe
secondary pneumococcal pneumonia, measured 26 h after the first or second dose of
dexamethasone (white-filled, n = 4 or 3, respectively) or mock therapy (dark gray-filled,
n = 6 or 5, respectively) combined with ampicillin treatment. (B) Albumin levels in
BALF supernatant harvested from mice with severe secondary pneumococcal pneumonia
26 h after the first or second dose of adjunctive dexamethasone (white-filled, n = 4 or 3,
respectively) or mock therapy (dark gray-filled, n = 6 at both time points) combined with
ampicillin treatment.
*P < 0.05 by Mann-Whitney U test. The bar graphs show the average ± SD.
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ampicillin treatment was initiated upon detection of SBP. Interestingly, early
dexamethasone treatment did not augment the survival improvement of ampicillin-treated
pneumonic mice; rather, it led to loss of its protective activity (Figure 4-6A). Survival of
ampicillin-treated mice with severe pneumonia dropped from about 70% with adjunctive
dexamethasone therapy (Figure 4-4A) to about 30% with early dexamethasone regimen
(Figure 4-6A). Furthermore, ampicillin-treated mice with mild pneumonia demonstrated
a modest, non-significant increase in mortality after early dexamethasone treatment as
compared to mock-treated group (Figure 4-6A). In addition, similar to the poor
morbidity outcome of adjunctive therapy in mice with mild pneumonia, early
dexamethasone treatment was associated with increased body weight loss from primary
influenza and delayed body weight regain after ampicillin treatment of SBP (Figure
4-6B).
Early Dexamethasone Treatment Suppresses Adaptive Immunity
Glucocorticoids are known to suppress adaptive immunity [235]. Therefore, we
hypothesized that the increased morbidity associated with early dexamethasone therapy
during primary influenza infection was due to suppressed adaptive immunity, leading to
elevated influenza viral titers and increased lung injury. We measured the numbers of T
cells in both BALF and post-lavage lungs on day 7 after influenza infection under early
dexamethasone or mock treatment (i.e., 24 h after the fourth dose of dexamethasone or
PBS). As expected, early dexamethasone treatment significantly reduced the absolute
numbers of CD4+ and CD8+ T cells in lungs as compared to mock treatment (Figure
4-7A). To determine if this reduction in the respiratory pool of T -cells was associated
with impaired influenza viral clearance, we measured influenza viral titers on day 7 p.i.
Early dexamethasone-treated mice had significantly higher influenza viral titers than
mock-treated mice (Figure 4-7B).
Adjunctive DABA Treatment Improves Survival of Ampicillin-treated Mice with
Secondary Pneumococcal Pneumonia
The findings that adjunctive dexamethasone therapy worsened the morbidity of
ampicillin-treated mice with mild SBP, reflected by the delayed body weight regain
(Figure 4-4B), put the proposed use of dexamethasone into question. Therefore, we
tested the efficacy of a novel immunomodulator drug, DABA, for treating SBP using the
same treatment regimen as dexamethasone. We found that adjunctive DABA therapy
improved survival of ampicillin-treated mice with severe or mild SBP in a rate similar to
that of adjunctive dexamethasone treatment. Combined DABA plus ampicillin treatment
could significantly increase the survival rate of mice with severe SBP from 0% to about
70%. In addition, adjunctive DABA therapy could rescue all ampicillin-treated mice with
mild SBP, but the increase in the survival rate was not statistically significant compared
to the mice group subjected to mock adjunctive therapy (Figure 4-8A and B).
In contrast to dexamethasone treatment, adjunctive DABA therapy did not worsen
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Figure 4-6.

Early dexamethasone treatment leads to loss of its protective activity

(A) Survival rates of co-infected mice with early dexamethasone or mock (PBS) therapy
started during primary influenza infection, and continued with ampicillin treatment after
detection of severe (Early Dexa-S, n = 7 or Early PBS-S, n = 5 respectively) or mild
(Early Dexa-M, n = 9 or Early PBS-M, n = 9, respectively) secondary pneumococcal
pneumonia. (B) Body weight loss curve of influenza-infected mice with early
dexamethasone or mock (PBS) therapy, challenged with bacteria on day 7 p.i, and treated
later with ampicillin after detection of mild secondary pneumococcal pneumonia (n = 9).
*P < 0.05,** P < 0.01 by Mann-Whitney U test (Panel B). Data are expressed as the
average ± SEM.
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Figure 4-7.

Early dexamethasone treatment suppresses adaptive immunity

(A) Absolute numbers of CD4 + and CD8+ T cells within alveolar airspaces (BALF), or in
post-lavage lungs of influenza-infected mice measured on day 7 p.i with early
dexamethasone or mock (PBS) therapy (n = 4 or 5, respectively). (B) Influenza viral titers
in post-lavage lungs of influenza-infected mice measured on day 7 p.i with early
dexamethasone or mock (PBS) therapy (n = 4 or 5, respectively).
*P < 0.05 by Mann-Whitney U test. The bar graphs show the average ± SD.
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Figure 4-8. Adjunctive 2,3-diacetyloxybenzoic acid treatment improves survival
of ampicillin-treated mice with secondary pneumococcal pneumonia
Survival rates and body weight loss curves of ampicillin-treated mice with either severe
(Panel A, n = 7 for each group) or mild (Panel B, n ≥ 8 for each group) secondary
pneumococcal pneumonia with adjunctive 2,3-diacetyloxybenzoic acid (DABA) or mock
(PBS) * therapy. (C) Absolute numbers of neutrophils within alveolar airspaces of mice
with severe secondary pneumococcal pneumonia, measured 26 h after the first or second
dose of adjunctive DABA (red-filled, n = 5 or 3, respectively) or mock therapy (dark
gray-filled, n = 6 or 5, respectively) combined with ampicillin treatment.
** P < 0.01 by log-rank test on the Kaplan–Meier survival data, *P < 0.05 by MannWhitney U test (Panel C). Data are expressed as the average ± SEM (Panel A and B), or
as the average ± SD (Panel C).
*
I used the same mock-treated groups in (Figure 4-4), as I used different drug treatment
in the same experimental setting.
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the morbidity of ampicillin-treated mice with mild SBP. This was implicated by
monitoring the body weight recovery of mice with mild SBP, as DABA-treated mice
showed comparable rate of body weight regain to the mice group with adjunctive mock
therapy (Figure 4-8A and B). Improved survival with combined DABA therapy of mice
with severe SBP was accompanied by significantly decreased neutrophil accumulation
after the second dose (Figure 4-8C).
Early DABA Treatment Does Not Worsen the Morbidity of Influenza-infected Mice
Another caveat of dexamethasone use that was revealed in our model of SBP is
the significant impact of changing its administration timing. We demonstrated that early
dexamethasone therapy during the primary influenza infection had a negative impact on
the course of influenza infection and was associated with increased morbidity of
influenza-infected mice. Therefore, we sought to test if early DABA treatment would
have similar bad outcomes as early dexamethasone therapy. Early DABA treatment was
initiated from day 3 until day 13 after influenza infection, while ampicillin treatment was
given upon detecting SBP. Early DABA treatment did not worsen the morbidity of
influenza-infected mice (Figure 4-9B). Nonetheless, early DABA therapy showed partial
loss of their protective activity against mortality of ampicillin-treated mice with severe
SBP (Figure 4-9A), in a pattern similar to that of early dexamethasone therapy.
Discussion
Historically, death from SBP was a common feature of all influenza pandemics in
the pre-antibiotic era [123]. Indeed, mortality from pneumococcal pneumonia
significantly decreased after the discovery of penicillin [236]. Nevertheless, SBP still
contributes significantly to morbidity and mortality during seasonal influenza and recent
influenza pandemics, despite the use of effective antibiotics [214]. Furthermore, rates of
mortality due to pneumococcal pneumonia have been relatively stable throughout the
antibiotic era even with the routine use of more advanced β-lactam antibiotics [237, 238].
In a similar pattern, ampicillin treatment of SBP in our murine model demonstrated
therapeutic failure here and in previous studies [202, 204, 234]. Despite its effective rapid
bactericidal activity and significant pneumococcal clearance, ampicillin therapy failed to
rescue more than 50% of mice with SBP. This has been previously attributed to rapid
bacterial cell wall lysis, accompanied by release of bacterial cell wall fragments
activating exuberant inflammatory responses in lungs, thereby leading to increased
morbidity and mortality [204].
As the degree of severity of SBP may affect ampicillin treatment outcomes, we
determined pneumococcal load in vivo using a sensitive non-invasive bioluminescence
imaging to approximate pneumococcal outgrowth in the co-infected lungs prior to
treatment, then classified SBP into mild or severe based on this surrogate for
pneumococcal load. Interestingly, ampicillin treatment caused disparate mortality rates in
mice with different degrees of pre-treatment severity of SBP. This finding suggests
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Figure 4-9. Early 2,3-diacetyloxybenzoic acid treatment does not worsen
morbidity of influenza-infected mice
(A) Survival rates of co-infected mice with early 2,3-diacetyloxybenzoic acid (DABA) or
mock (PBS)* therapy started during primary influenza infection, and continued with
ampicillin treatment after detection of severe (Early DABA-S, n = 4 or Early PBS-S, n =
5) or mild (n = 9 for each group) secondary pneumococcal pneumonia. (B) Body weight
loss curve of influenza-infected mice with early DABA or mock therapy, challenged with
bacteria on day 7 p.i, and treated later with ampicillin after detection of mild secondary
pneumococcal pneumonia (n = 9). Data are expressed as the average ± SEM.
*
I used the same mock-treated groups in (Figure 4-6), as I used different drug treatment
in the same experimental setting.
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a direct correlation between pneumococcal load size at the onset of antibiotic therapy and
the poor survival outcomes during antibiotic treatment of SBP. This relationship was
inferred through modulating the degree of lung immunopathology induced after bacterial
cell lysis with ampicillin. Thus, ampicillin treatment of mice with severe SBP aggravated
lung immunopathology compared to those with mild SBP. Yet, both groups of mice
showed comparable rapid pneumococcal clearance after the first two doses of ampicillin.
The differential ampicillin treatment-associated immunopathology was evident on the
second day of treatment, when mice with severe SBP had significantly increased
accumulation of neutrophils within the alveolar airspaces, and increased pulmonary
vascular permeability compared to ampicillin-treated mice with mild SBP.
To protect against the lung immunopathology induced during antibiotic treatment
of SBP, we used the standard anti-inflammatory drug dexamethasone, which is well
known for its potent inflammatory suppressive and immunomodulatory activities.
Dexamethasone is one of the synthetic corticosteroids that are clinically used to treat
several inflammatory disorders and autoimmune diseases [219]. However, the benefits of
adjunctive corticosteroid therapy of CAP have been under debate for a long time [227,
239] due to conflicting results from different studies of this potential therapy [220, 221,
223, 224, 240-242]. In our murine model of SBP, adjunctive dexamethasone treatment
improved survival rates of pneumonic mice. Interestingly, best results were observed in
ampicillin-treated mice with severe SBP, in which treatment-associated
immunopathology was significantly attenuated. This was achieved after the second dose
of dexamethasone, where accumulation of neutrophils within the alveolar airspaces was
significantly reduced compared to mock plus ampicillin-treated mice. Furthermore, a
significant decrease in pulmonary vascular permeability was observed one day after the
first dose of dexamethasone. These treatment outcomes of severe SBP in our murine
model are consistent with several randomized controlled trials that showed that the
beneficial outcomes of adjunctive corticosteroids therapy are limited to severe cases of
community-acquired pneumonia in humans [220, 221, 241, 242]. We used
dexamethasone at a dose (2.5 mg/kg) that was previously shown to suppress the
pulmonary inflammatory responses in various murine models of airway inflammation,
such as endotoxin-induced acute lung injury, house dust-induced asthma, and allergic
bronchopulmonary aspergillosis [243-245]. Other researchers have shown that
dexamethasone treatment from days 3-14 after highly pathogenic avian influenza
infection had no beneficial effect on acute respiratory distress syndrome caused by the
H5N1 infection in mice [246], data which support our findings regarding the poor
outcomes associated with early dexamethasone treatment during primary influenza
infection. Additionally, our dose of dexamethasone is clinically relevant to the
corticosteroid doses, which showed beneficial outcomes as adjunctive therapy of adult
humans with severe CAP [247-249].
However, corticosteroids have potential drawbacks, as they can cause systemic
immunosuppression [219, 235]. Therefore, we tested the effect of early administration of
dexamethasone during primary influenza infection to determine whether it would remain
beneficial in ampicillin-treated mice with severe SBP. As expected, early dexamethasone
treatment significantly decreased numbers of both CD8 + and CD4+ T cells in the lungs on
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day 7 after influenza infection. This was associated with delayed influenza viral clearance
and accelerated morbidity progression during primary influenza infection and before
secondary pneumococcal challenge. This had a negative impact on ampicillin treatmentassociated fatality with eventual loss of the protective functions of the adjunctive
dexamethasone regimen in mice with either mild or severe SBP.
Therefore, we tested the efficacy of another novel immunomodulator drug –
DABA that could effectively attenuate the endotoxin-induced acute lung injury in 2
different animal models by decreasing the pulmonary vascular permeability. Adjunctive
DABA therapy improved survival of ampicillin-treated mice with SBP, with more
pronounced effect on mice with severe SBP associated with significant decrease in
neutrophil accumulation within the alveolar airspaces. Additionally, DABA did not
worsen the morbidity of mice with mild SBP. Furthermore, early DABA therapy during
influenza infection did not have detrimental effect on the morbidity of influenza-infected
mice. Nevertheless, early DABA therapy did not augment the improved survival of
adjunctive DABA-treated mice, but rather it led to a partial loss of its protective
functions.
Taken together, our data suggest that the general unrestricted use of adjunctive
corticosteroid therapy during influenza or CAP is likely not warranted. Several factors
may participate in balancing the beneficial and detrimental outcomes after systemic
corticosteroid treatment, such as the drug dose, the onset and duration of treatment, the
causative infectious agents, and whether the pneumonia is caused by a single bacterial or
viral agent or is due to a co-infection. Our findings demonstrate that the bacterial burden
during pneumonia has an impact on treatment outcomes with larger burdens generating
more inflammation and higher mortality upon antibiotic-mediated lysis. Furthermore,
these experiments support the observed preferential beneficial activity of corticosteroids
when combined with antibiotic treatment in severe cases of CAP. Interestingly, our data
point out a significant impact of the timing of dexamethasone therapy on its protective
functions, which would be of great importance in modifying treatment protocols of
severe cases of SBP following viral infections. Thus, our experiments suggest that early
corticosteroid administration during primary influenza infection can worsen adaptive
immunity against influenza infection, thereby increasing viral titers and consequently
increasing viral-mediated lung damage. Late treatment with steroids, when virus has
cleared and inflammation is driving disease, can improve outcomes. Additionally, our
preliminary experiments on adjunctive DABA therapy showed promising results for
treating CAP without detrimental impact on mild cases. However, it would be interesting
to investigate the mechanism of action of DABA treatment in the context of antibiotic
therapy of SBP, which may promote its clinical use during treatment of CAP. Finally, our
study further advances an animal model with sophisticated tools for classifying the
severity of bacterial pneumonia, which will help investigating the efficacy of different
immunomodulators as adjunctive therapy, as well as different or new classes of
antibiotics for treatment of SBP.
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CHAPTER 5.

GENERAL DISCUSSION, INSIGHTS, AND FUTURE
DIRECTIONS

Bacterial super-infections have been implicated to mediate the increased
morbidity and deaths during influenza pandemics, epidemics, and even seasonal
influenza, with consequent tremendous socioeconomic burden [36, 120]. Their great
clinical impact was initially observed long ago, when a French physician, René Laennec,
observed the increased frequency of “double” pneumonia as a fatal complication during
an influenza epidemic in 1803 [121]. Later, during the 1918 influenza pandemic, many
investigators also pointed out the significant contribution of SBP in causing the most
deaths in an event that exceeded 30 million fatal cases worldwide. Even though the
discovery of penicillin and other antibiotics led to a significant reduction in the mortality
rate due to SBP, bacterial super-infections remained a serious medical problem during
influenza outbreaks and pandemics, such as the 1957, 1968, and 2009 influenza
pandemics [35].
S. pneumoniae is the predominant secondary bacterial pathogen during influenza
infections. Because of its nasopharyngeal colonization in some asymptomatic carriers,
pneumococcus can easily spread among influenza-infected patients via respiratory
droplet inhalation. However, unique lethal synergism has been observed between primary
influenza infections and secondary pneumococcal infections.
Although many investigators have established the respiratory viral-bacterial
synergism in animal models, the mechanisms underlying it are still unclear. A complete
understanding of this synergism was hindered by the commonly believed concept of
influenza-induced epithelial damage as the major predisposing factor to secondary
bacterial infections. Indeed, some influenza viral virulence factors displayed important
roles in this synergism. However, these factors are basically critical for viral
pathogenesis, which is a prerequisite for secondary bacterial infections. Thus, this
concept would be valid for highly virulent influenza virus strains. However, the findings
that even mild seasonal influenza viruses can also enhance the vulnerability to secondary
bacterial infections have suggested the existence of more critical mechanisms for this
unique synergism drawing the attention to explore possible alterations of the host
immunity during influenza infections.
Alterations in host immunity have become an increasingly important aspect of the
influenza-mediated predisposition to SBP. Among numerous alterations in host immune
responses during influenza infections, defects in pulmonary antibacterial immunity have
been observed explaining the strikingly increased vulnerability to bacterial infections.
Recently, several mechanisms of the defects in various antibacterial immune effectors
have been proposed in influenza-infected lungs [147]. Among those immune effectors,
resident AMs play a central role in effective protection against bacterial pathogens in the
lungs.
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Impact of Influenza Infections on Resident Alveolar Macrophages In Vivo
Early studies in the 20 th century indicated defective phagocytic functions of AMs
during mild and severe influenza infections. [145-148]. Recently, it’s been suggested that
the AM dysfunction during influenza infections is due to IFNγ-induced downregulation
of the expression of MARCO receptor [101], a scavenger receptor on the surface of AMs,
which was implicated in non-opsonized phagocytosis of pneumococci [97]. They
proposed this mechanism of defective phagocytosis of AMs only when IFNγ secretion is
significantly elevated in the lungs, which is temporally related to adaptive immune cell
accumulation during the resolution phase of sublethal influenza infection [101, 150].
However, this mechanism fails to explain the common clinical observations and studies
on animal models of bacterial co-infections that showed increased predisposition to
secondary bacterial infections during the first week of influenza, even before the
appearance of adaptive immune cells and the peak of IFNγ production. In addition,
another study showed that augmented IFNγ production in the lungs can provide
protective activity, possibly by increasing neutrophil influx, against lethal pneumococcal
pneumonia [205].
Despite the repeated investigation of influenza infection impact on resident AMs,
the results were confounding, because most studies were performed using in vitro
infection systems, which may not be pathologically relevant to the in vivo influenza
infections due to differences in the microenvironment conditions [47, 48, 51]. Even
though some investigators have studied the alterations of AM functions in vivo, the
misrepresentation of resident AM subset by the total macrophage population harvested in
BAL during influenza infections, without strict discrimination approaches, may lead to
profoundly erroneous conclusions about the actual state of resident AMs. As a part of the
innate immune responses to influenza infections, circulating macrophages and monocytes
are recruited to and accumulate in influenza-infected lungs. Therefore, macrophages
isolated by BAL process would represent heterogeneous populations of macrophages
with different phenotypes. Thus, some investigators implied no change or a significant
increase in the numbers of AMs associated with functional phenotype changes during in
vivo influenza infections [101, 185].
In contrast, I argue that most of these studies showed erroneous conclusions about
the mechanistic influence of influenza infection on resident AMs due to the lack of
approaches discriminating resident AMs from the recruited exudate inflammatory
macrophages during influenza infection. Thereby, these technical limitations have
hindered clear understanding of mechanisms underlying the defects in their protective
functions during influenza infections.
To determine the impact of sublethal influenza infection on resident AMs in vivo,
I initially characterized different lung-resident macrophage subsets using flow cytometry
analyses coupled with a quite novel in vivo labeling approach through intranasal
administration of the fluorescent PKH26-PCL dye. This in vivo labeling technique
selectively labeled lung-resident macrophages with efficient stability for more than 2
weeks. Comparisons of the fluorescence intensity of the intracellular PKH26-PCL dye
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facilitated successful discrimination between the two major subsets of lung-resident
macrophages – AMs and IMs, and could clearly distinguish them from all myeloid
subsets recruited during influenza infection.
Surprisingly, I found that sublethal influenza infections using the mouse-adapted
PR8 influenza or a human clinical isolate of 2009 pandemic H1N1 influenza virus strains
caused significant depletion of resident AMs, but not IMs, with a maximum nadir on day
7 after influenza infection. AM depletion was temporally aligned with the impaired early
pneumococcal clearance within the alveolar airspaces from day 3 to day 9 after influenza
infection. Later, the AM pool was fully replenished leading to recovery of antibacterial
immunity in the lungs. Synergistic interaction between primary influenza and secondary
pneumococcal infections was successfully implemented during AM depletion phase,
reflected by the progression of lethal secondary pneumococcal pneumonia.
What suggested the causal relationship between AM depletion and increased
permissiveness to SBP are the protective outcomes of the immunomodulation approach
that we used to expand the pool size of resident AMs during influenza infection. Local
pulmonary GM-CSF treatment could significantly expand the pool size of IMs with
partial expansion of AMs during influenza infection. These effects could partially restore
the protective early bacterial clearance in the lungs and protected co-infected mice
against development of SBP.
Insights
Because of their unique anatomical position at the interface between air and
alveolar epithelial cells and continuous exposure to the external environment, resident
AMs have a pivotal role for maintaining protection in the lungs against inhaled noxious
agents, including environmental particles and bacterial pathogens. Their functions rely on
two unique features: high phagocytic capacity and immunosuppressive nature. Therefore,
pathological AM depletion during mild influenza infections would have several
consequences on the innate and adaptive immune responses in the lungs.
We examined the first obvious consequence of AM depletion during influenza
infections which is the expected defect in the first line of pulmonary innate immunity
protecting against bacterial pathogens. Indeed, the early bacterial clearance was notably
impaired during the AM depletion phase. Pulmonary phagocytic capacity was carefully
tested using small inocula of pneumococci rather than big inocula that were used in
almost all animal models of secondary bacterial infections following influenza. The use
of relatively big inocula of pneumococci for studying protective functions of resident
AMs is considered a critical limitation in these animal studies, because these big inocula
bypass the phagocytic threshold of resident AMs, and perhaps they are not relevant to
clinical settings. In addition, in some studies bacterial clearance was examined at later
time points, such as 24 and 48 h after bacterial inoculation, when neutrophils accumulate
as the second line of innate defense. Thereby, they ended up studying neutrophil
functions rather than that of resident AMs.

80

Consequently, lethal SBP was successfully developed if influenza-infected mice
were secondarily infected by small inocula of pneumococci during the AM depletion
phase. Taken together, the novel finding of AM depletion during influenza infection
implied a novel potential mechanism of the pulmonary viral-bacterial synergism which
coincides with the order and timings of SBP in humans [198]. In addition, this
mechanism may sound more reasonable to explain the increased vulnerability of
influenza-infected hosts to different multiple bacterial pathogens, instead of specific
viral-bacterial interactions.
Indeed, two recent studies confirmed our data using completely different, yet
elegant, approaches. In the first study, the research group used mice with genetically
engineered fluorescent reporter in tissue-resident macrophages, including AMs. They
demonstrated dramatic cytoablation of lung-resident macrophages 6 days after sublethal
PR8 influenza infection [173]. Furthermore, they also showed that most of the recovery
of lung-resident macrophage, after diphtheria toxin-induced depletion, was achieved by
stochastic local cellular proliferation in a macrophage colony-stimulating factor (MCSF)- and GM-CSF-dependent manner but independently of IL-4 [173]. These data
correlate with our findings about the ontogeny of replenished AMs after influenza
infection, which we proposed to be achieved by local proliferation of labeled IMs and
their maturation into resident AM phenotype (Figure 2-9).
Additionally, a recent study using mathematical modeling of bacterial coinfection, with the same infectious agents as in our model, expected significant loss of
about 90% of AM functions by day 7 after sublethal PR8 influenza infection [250]. We
experimentally demonstrated the same results with depletion of about 90% of resident
AMs on day 7 after sublethal PR8 influenza infection. Furthermore, they hypothesized
that this AM dysfunction is one of the major mechanisms underlying the increased
influenza-pneumococcal co-infection synergism supporting our experimental data [250].
There may also be other effects of AM depletion during influenza infections,
which may not be related to their phagocytic functions, rather stem from their
immunosuppressive activities demonstrated in several in vitro and in vivo studies. They
display poor antigen presenting abilities and consequently poor T cell stimulation, as well
as inhibitory effects on local DC functions [175-178]. Recently, lung-resident
macrophages were shown to be critical mediators of the airway immune tolerance
through inducing the generation of Foxp3+ regulatory T cells in a TGF-β- and retinoic
acid-dependent manner [251]. Indeed, artificial depletion of pulmonary macrophages
using clodronate liposomes abrogated the immunosuppressive state while augmented
adaptive immune responses in the lungs [252]. In addition, their artificial depletion was
shown to increase secondary IgE responses and infiltration of B cells and T cells into the
lungs after allergen exposure [253], as well as increase NK cells and functionality of
CD4+ and CD8+ T cells during respiratory pneumovirus infection in mice [254].
Furthermore, a recent study using a murine model of ovalbumin-induced acute asthma
demonstrated that clodronate-mediated depletion of AMs increased the airway infiltration
of inflammatory immune cells, eosinophils and lymphocytes as well [255]. In contrast,
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the allergic airway inflammation and hyperresponsiveness were attenuated after adoptive
transfer of naive AMs [255, 256]. However, liposome-encapsulated clodronate may also
induce depletion of IMs along with AMs, which may complicate the results, as IMs have
stronger antigen presenting abilities and stimulatory functions than AMs. In contrast,
pathological depletion of AM subset alone may have even more profound impact on the
adaptive immune responses and allergic reactions in influenza-infected lungs.
Based on the kinetics of the adaptive immune responses during influenza
infections, the peak of their cellular effectors recruitment and functionality in the lungs is
quite coincident with the nadir of AM depletion at the end of the first week of influenza
infection. This correlation may give novel insights about a probable role of AM depletion
in releasing the immunosuppressive brakes in the lungs. Thereby, allowing an efficient
functionality of influenza-specific adaptive immune cells in the lungs.
Among other probable outcomes of AM depletion during influenza infections is
the influence on the progression of airway hypersensitivity and asthma by possibly
lowering the activation threshold for allergen-specific immune cells. Indeed, influenza
infections in infants have been recognized as a potent risk factor for asthma development
later. Furthermore, asthma exacerbation has been well documented during seasonal and
pandemic influenza infections and other respiratory viral infections [55, 257, 258]. In
addition, a recent study, in an infant mouse allergy model using house dust mite,
demonstrated exacerbation of airway allergic responses when they get infected by
influenza viruses [259]. Yet, the mechanisms underlying this synergism have not been
completely elucidated.
Future Directions
The question of how influenza viruses cause depletion of resident AMs in vivo
still needs to be fully answered. Indeed, some previous studies showed direct influenza
infection of AMs, followed by apoptosis [260, 261]. However, infection was observed in
only a small percentage of AMs, and thus cannot totally account for the significant
depletion observed. In contrast, some investigators showed no apoptotic events of AMs
during influenza infections in pigs [262]. I believe that this significant AM depletion
during sublethal influenza infections might have resulted from changes in their key
survival signals in the lung microenvironment. These survival signals are probably
altered and/or reduced by the damage and death of influenza-infected epithelial cells. To
address this possibility, cross-talk between resident AMs and respiratory epithelial cells
needs to be explored carefully and tested for major alterations during influenza
infections. In addition, it is critical to determine the type of resident AM cell death in
vivo during influenza infection, which may elucidate signals causing this depletion
process. Generally, there are several ways to determine the type of cell death, including
microscopic examination of the morphological changes in the cellular structures to
differentiate, for example, between apoptotic and non-apoptotic cell death events. Also,
monitoring certain biochemical changes inside the cells may indicate the type of cell
death. However, these methods may have some intrinsic technical limitations leading to

82

detecting cell death only under limited experimental settings. Also, some techniques may
not be able to define the exact cell death type, as the detected features may overlap with
various types of cell death [263, 264]. Therefore, several techniques with unrelated
methodologic principles should be performed for better assessment of the type of cell
death.
Different respiratory viral infections have been associated with secondary
bacterial infections. Although we found significant depletion of the resident AMs during
sublethal influenza infections using two different strains of H1N1 influenza A viruses as
well as another influenza B virus strain, it will be essential to determine the impact of in
vivo infections by other influenza A virus subtypes on lung-resident macrophages. In
addition, it will be of paramount importance to test if other respiratory viruses, known to
increase predisposition to SBP such as respiratory syncytial virus and parainfluenza
viruses, can also induce resident AM depletion. If this novel mechanism is observed with
different respiratory viruses, it will suggest AM depletion as a general mechanism for the
increased respiratory viral-bacterial synergism. Thus, exploring new prophylactic and
therapeutic interventions targeting this mechanism would be of great significance to
reduce the global burden of SBP during seasonal influenza and any future influenza
pandemics. In addition, testing different influenza virus strains for AM depletion ability
may infer novel features contributing to viral infection outcomes away from the classical
viral virulence determinants.
Another serious clinical aspect associated with influenza infections is the
increased risk for airway hyperresponsiveness and asthma exacerbation. Therefore,
establishing animal models of influenza infections concomitant with acute or chronic
asthma pathogenesis may reveal novel interactions elicited by the loss of lung
immunosuppressive state during resident AM depletion.
Treatment Strategies of Secondary Bacterial Pneumonia Following Influenza
Acute lower respiratory tract infections represent a major public health problem
causing significant clinical and socioeconomic burdens worldwide. Compared to other
serious infections, they are the leading cause of morbidity and mortality in the United
States [120]. Pneumonia is caused by the infection of the alveolar airspace, associated
with accumulation of inflammatory cells and secretions in the alveoli causing acute
inflammatory lung injury and impaired gas exchange. Treatment of this serious medical
problem has been challenging. Despite the wide use of antibiotics since the advent of
penicillin to the clinical use in 1940s, the significant mortality rates of influenza and
pneumonia patients have persisted with minor changes for more than 50 years [119, 120].
Many patients progress from uncomplicated respiratory viral infections to severe
complicated pneumonia with a high case fatality rate despite adequate antibiotic use, such
as patients with SBP following influenza [212]. A recent example of this treatment failure
was evident during the 2009 H1N1 influenza pandemic, in which about one third of the
severe or fatal cases were complicated by SBP [35]. Therefore, in addition to new
antibiotic classes, we definitely need a non-antibiotic approach for the effective
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management of pneumonia. This will require a better understanding of lung
immunopathology and the poor outcomes during antibiotic treatment of pneumonic
patients.
One of the enduring questions in this field has been whether adjunctive
corticosteroid treatment of pneumonia can improve the outcomes. [227, 239]. The answer
to this question has been perplexed by the mixed results shown in several clinical studies
of adjunctive corticosteroid use for treating pneumonia in humans [220, 221, 223, 224,
240-242]. Some of these clinical trials showed beneficial effects, while others showed
detrimental or no effect after combining corticosteroids with the standard antibiotic
treatment of pneumonia.
Using a well-established mouse model of SBP following influenza infection, we
tested the hypothesis that adjunctive corticosteroid therapy can modulate antibioticinduced immunopathology during treatment of severe cases of SBP. We also tested the
impact of early corticosteroid treatment on primary influenza infection and the outcomes
of ampicillin treatment of SBP under these settings. We could monitor the progression of
SBP in vivo using bioluminescence imaging, which is a non-invasive accurate surrogate
measure of the pneumococcal burden in the lungs. Thus, prior to antibiotic treatment, we
classified the pneumonic mice into groups with mild or severe SBP based on the
pulmonary bacterial burden.
First, we found an interesting direct correlation between the pneumococcal
burdens in the lungs at the onset of ampicillin treatment and the treatment outcomes.
Larger bacterial burdens generated more inflammation upon ampicillin-mediated
bacterial cell lysis. The release of copious amounts of bacterial PAMPs aggravated the
ongoing inflammatory responses in the lungs by activating the inflammatory signaling
pathways of different PRRs, including TLR2 detecting pneumococcal cell wall fragments
[204]. Thus, the increased lung immunopathology associated with antibiotic treatment of
mice with severe SBP eventually caused higher mortality.
Additionally, adjunctive dexamethasone therapy could significantly rescue severe
cases of SBP after dampening ampicillin treatment-induced inflammation in the lungs
and improving pulmonary vascular permeability. However, it worsened the morbidity of
mice with mild SBP reflected by delayed recovery of their body weight.
On the other hand, the early start of dexamethasone therapy during influenza
infection resulted in loss of its protective functions. Corticosteroids do not only display
potent anti-inflammatory activities, but can also cause systemic immunosuppression
[219, 235]. We examined if early dexamethasone therapy had detrimental impact on the
adaptive immunity against primary influenza infection. Indeed, early dexamethasone
treatment significantly reduced numbers of CD8 + and CD4+ T cells in the lungs on day 7
after influenza infection. This was associated with delayed influenza viral clearance and
consequently increasing viral-mediated lung damage, which was implied by the
accelerated body weight loss before secondary pneumococcal challenge.
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We also tested the efficacy of DABA, a novel immunomodulator that was shown
to attenuate endotoxin-induced acute lung injury [230]. Combined DABA therapy with
ampicillin treatment of SBP demonstrated protective effect similar to that of
dexamethasone. However, it did not have a negative effect on the morbidity of mice with
mild SBP after either adjunctive or early DABA treatment regimen. Nonetheless, its early
administration during influenza infection was associated with partial loss of its protective
functions.
Insights
Our findings highlighted several important aspects about the efficacy of
adjunctive corticosteroid therapy in CAP, which may give insights explaining part of the
discrepancies in the clinical studies of corticosteroid use in CAP. The first aspect is the
impact of the severity of pneumonia and the bacterial load size in the lungs at the onset of
antibiotic treatment on the adjunctive therapy outcomes. Indeed, the differential treatment
outcomes in our murine model of SBP are consistent with several randomized controlled
clinical trials that demonstrated positive outcomes of adjunctive corticosteroid therapy
only in the severe cases of CAP in humans [220, 221, 241, 242]. However, the criterion
that we used for defining the severity in our murine model of SBP relies on the bacterial
burden in the lungs, different from the clinical criteria for severe CAP in humans, which
depend mostly on the lung functions.
Another critical aspect is the timing of dexamethasone therapy. Our experiments
suggested that early dexamethasone treatment during the respiratory viral infections, such
as influenza, would be associated with detrimental outcomes due to its suppressive
effects on the anti-viral adaptive immunity. This aspect would be of paramount
importance in patients with CAP that have simultaneous viral and bacterial etiologies.
Therefore, we propose that the best treatment outcomes can be achieved if
dexamethasone is administered during the resolution phase of the primary viral infection
in conjunction with antibiotic treatment of the complicating bacterial pathogen. Taken
together, adjunctive corticosteroid therapy can be used with great efficacy in the severe
cases of CAP with careful consideration of the timing of treatment and the onset of any
suspected primary viral infection. These findings will be interesting to the translational
researchers, clinicians, and public health officials for better therapeutic management of
lower respiratory tract infections.
Future Directions
Our findings showed that the murine model of SBP can be used as a good
surrogate for preliminary studies on novel immunomodulation approaches during
antibiotic treatment of CAP. This model showed results that were clinically relevant to
the randomized clinical trials of adjunctive corticosteroid therapy of CAP in humans.
Moreover, in vivo bioluminescence imaging proved to be an accurate powerful tool for
monitoring the bacterial outgrowth as well as the bacterial clearance in the lungs after
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antibiotic treatment, which was also showed in several previous studies [202, 204, 265,
266]. Therefore, our murine model of SBP and the powerful bioluminescence imaging
tool would form a very useful technical approach for objective evaluation of the efficacy
of novel prophylactic and therapeutic interventions for treating SBP following influenza.
Indeed, we started exploring novel immunomodulators that can be used for either
preventing the increased lung immunopathology elicited during antibiotic treatment of
SBP, or promoting the lung tissue repair processes. DABA is a novel immunomodulator
that could improve survival of antibiotic-treated mice with severe SBP when given as
adjunctive therapy. Furthermore, it did not affect body weight recovery after treatment,
which was a potential drawback of adjunctive dexamethasone treatment of mice with
mild SBP. DHBA, the active form of DABA, has multiple activities, such as strong iron
chelation and free radical scavenging. DHBA has also been shown to inhibit the activity
of matrix metalloproteinase-2 (MMP-2), which may help ameliorate the lung tissue
damage during pneumonia [267]. MMP-2 is a member of the matrix metalloproteinases
(MMPs) that have diverse catalytic functions, mainly facilitating degradation of different
components of the extracellular matrix required for tissue remodeling [268].
Interestingly, increased levels of some MMPs were strongly correlated with the clinical
severity of CAP and were suggested to contribute to increased lung tissue destruction
[269]. Therefore, the probable MMP-inhibitory functions of DABA may mediate its
protective functions during treatment of severe SBP. However, further investigation is
needed to determine the exact mechanism of action of DABA treatment. In addition,
exploring other immunodulators is crucial to help prevent the antibiotic treatment failure
in recuing severely pneumonic patients by suppressing the exuberant inflammatory
responses in the lungs and/or promoting the lung tissue repair process.
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